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Thymic stromal lymphopoietin (TSLP) is a cytokine produced mainly by epithelial cells in 
response to inflammatory or microbial stimuli and binds to the TSLP receptor complex, a 
heterodimer composed of TSLP receptor (TSLPR) and IL-7 receptor α (CD127). TSLP 
activates multiple immune cell subsets expressing the TSLP receptor complex and plays a role 
in several models of disease. Although human monocytes express TSLPR and CD127 mRNAs 
in response to the TLR4 agonist LPS, their responsiveness to TSLP is ill-defined. We 
demonstrate that TSLP enhances human CD14+ monocyte CCL17 production in response to 
LPS and IL-4. Surprisingly, only a subset of CD14+ CD16- monocytes (TSLPR+ mono) 
expresses TSLP receptor complex upon LPS stimulation in an NF-κB- and p38-dependent 
manner. Phenotypic, functional and transcriptomic analysis revealed specific features of 
TSLPR+ mono, including higher CCL17 and IL-10 production and increased expression of 
genes with important immune functions (i.e. GAS6, ALOX15B, FCGR2B, LAIR1). Strikingly, 
TSLPR+ mono express higher levels of the dendritic cell marker CD1c. This evidence led us 
to identify a subset of peripheral blood CD14+ CD1c+ cells that expresses the highest levels of 
TSLPR upon LPS stimulation. The translational relevance of these findings is highlighted by 
the higher expression of TSLPR and CD127 mRNAs in monocytes isolated from patients with 
Gram-negative sepsis compared to healthy controls. Our results emphasize a phenotypic and 
functional heterogeneity in an apparently homogeneous population of human CD14+ CD16- 
monocytes and prompt further ontogenetic and functional analysis of CD14+ CD1c+ and LPS-
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1.1 Thesis: an overview and aim of the project 
Thymic stromal lymphopoietin (TSLP) is a cytokine produced mainly by epithelial cells in 
response to inflammatory or microbial stimuli (1). TSLP binds to the TSLP receptor complex, 
a heterodimer composed of TSLP receptor (TSLPR) and interleukin (IL)-7 receptor α (IL-7R-
α or CD127), and activates several signaling pathways, including the Janus kinase/signal 
transducer and activator of transcription (JAK-STAT5) pathway (2). TSLP receptor complex is 
expressed by epithelial cells and also several immune cell subsets, including dendritic cells 
(DCs). Importantly, several lines of evidence support a model in which TSLP activation of 
DCs results in Th2 differentiation in vitro and type 2 immunity in vivo (3, 4). As such, TSLP 
has been involved in the development of atopic diseases, tissue remodeling and in the 
modulation of the immune response to ectoparasite infections and cancers (1, 5). Nevertheless, 
the breadth of TSLP activity is not limited to type 2 immunity-related conditions. For 
example, TSLP is expressed in psoriatic lesions and instructs CD40 ligand (CD40L)-activated 
DCs to produce IL-12 and IL-23, which play a central role in psoriasis pathogenesis (6, 7). This 
cytokine has also been implicated in the pathogenesis on rheumatic diseases, at least in part 
by activating DCs (8). Finally, TSLP dampens myeloid cell inflammatory response in an 
experimental model of sepsis (9). Thus, understanding the response of myeloid cells (i.e. DCs, 
macrophages, neutrophils and monocytes) to TSLP may be relevant for several physiologic 
and pathologic conditions. Although human monocytes stimulated with lipopolysaccharide 
(LPS), the major component of the outer membrane of Gram-negative bacteria, express 
TSLPR and CD127 mRNAs (10), their responsiveness to TSLP is ill-defined. 
Activation of DCs with TSLP induces several phenotypic and functional responses, 
including the production of the chemokine CCL17/Thymus and activation regulated 
chemokine (TARC) that promotes the recruitment of CCR4-expressing cells (e.g. T helper 
[Th] 2 and regulatory T [Treg] lymphocytes) (1). Monocytes and macrophages activated with 
IL-4 or IL-13 also produce CCL17 in a STAT6-dependent manner (11, 12). Interestingly, TSLP 
and IL-4 or IL-13 synergize to induce CCL17 production by mouse macrophages (13). We 
have shown that the STAT5-activating cytokines IL-3 and GM-CSF synergize with IL-4 to 
enhance CCL17 production by human monocytes and macrophages (14). Since TSLP activates 
STAT5, we reasoned that also TSLP could enhance CCL17 production by human monocytes 
activated with LPS and IL-4. By investigating human monocyte responsiveness to TSLP, we 
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unexpectedly found that only a subset of human CD14+ monocytes express the TSLP receptor 
complex upon LPS stimulation and proceeded to characterize this subset. We demonstrate that 
TSLPR+ monocytes express distinct phenotypic, functional and transcriptomic profiles 
compared to TSLPR- monocytes, and are also enriched for a subset of CD14+ CD1c+ 
monocytes. The translational relevance of these findings is highlighted by the higher 
expression of TSLPR and CD127 mRNAs in monocytes isolated from patients with Gram-
negative sepsis compared to healthy controls. 
 
1.2 The immune system 
The immune system protects an organism from harmful invading pathogens, such as 
bacteria, viruses, fungi, parasites, and can be divided into the innate and adaptive immune 
system.  
The innate immune system play an important role in host defense in the early stages of 
infection through non-specific recognition of a pathogen, while the main characteristics of 
adaptive immunity are specific recognition of pathogen leading to the generation of pathogen 
specific long-term memory (15). Moreover, innate immune cells (i.e. monocytes and 
macrophages) may be exposed to different and sometimes opposing stimuli in a sequential 
manner, and the priming stimulus may exert a significant control over the response to 
subsequent stimuli. This phenomenon, which is referred to as “innate immune memory” or 
“trained immunity” (16, 17, 18). 
Innate immune cells are largely derived from myeloid hematopoietic precursors, and 
include neutrophils, eosinophils, basophils, macrophages, monocytes, DCs, and mast cells. A 
few innate (or innate-like) immune cells are derived from lymphoid hematopoietic precursors, 
and include natural killer (NK) cells, NKT cells, and gamma/delta (γδ)-T cells. The innate 
immune response relies on recognition of conserved structures on pathogens, termed 
pathogen-associated molecular patterns (PAMPs) , through a limited number of germ line-
encoded pattern recognition receptors (PRRs), and toll-like receptors (TLRs) is the most 
extensively studied class of PRRs (19). The different TLRs can be activated in response to 
different exogenous and endogenous ligands. An example is lipopolysaccharide (LPS), which 
binds to and activates its receptor TLR4, leading to expression of pro-inflammatory factors 
such as the cytokine tumor necrosis factor (TNF)-α (20). 
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Adaptive immunity is largely mediated by T and B cells, acting through  pathogen-specific 
surface receptors (T cell receptor [TCR] and B cell receptor [BCR], respectively). B cells are 
responsible for secreting antibodies, while T cells mediate more cellular effector responses 
(Figure 1) (21). 
 
1.2.1 Monocytes 
Monocytes are innate immune cells that circulate in the blood, bone marrow, and spleen 
and migrate from blood to tissues during infection (22).  
They are members of the mononuclear phagocyte system, a family of myeloid cells that 
comprises monocytes, DCs and macrophages. Human monocytes are distinguished by their 
surface expression of CD14 (migratory monocytes) and CD16 (patrolling monocytes), and 
three human cell subsets can be characterized, namely classical CD14++CD16−, intermediate 
CD14++CD16+ and non-classical CD14+CD16++ monocytes (23, 24).  The classical and 
intermediate subsets were most closely related among the subsets, while the non-classical 
subset was the most distant subset. 
Circulating monocytes exhibit a diameter of approximately 7–8 μm. However, monocytes 
can maturate into macrophages during inflammation and injury and reach diameters of 15–20 
μm. In response to infection, inflammation or tumor, monocytes, called ”inflammatory 
monocytes”, rapidly emigrate into tissue, and there acquire a wide variety of properties that 
are specifically associated with the local processes that led to their accumulation. Monocyte-
derived macrophages are commonly classified into “pro-inflammatory” (M1-like) and “pro-
resolving” or “anti-inflammatory” (M2-like) (25). 
Monocytes can differentiate also into DCs. Dermal CD14+ DCs, and intestinal 
CD103−CD172a+ DCs potentially represent populations of monocyte-derived cells. In 
inflamed tissues, the “inflammatory DCs” expressing CD1c, CD1a and CD14 are also likely 






1.3 Thymic stromal lymphopoietin  
TSLP is an epithelial derived cytokine, whose gene is located on chromosome 5q22.1, and 
it exerts its biological function through TSLP receptor complex that consists of a unique 
common γ (γc) chain-like TSLP receptor and the IL-7 receptor α chain (2). The TSLP receptor 
complex is expressed by hematopoietic cells, including T cells, B cells, NKT cells, 
macrophages, basophils, DCs, as well as some non-hematopoietic cell lineages, such as 
epithelial cells, suggesting that TSLP can act on a wide range of cell types. In fact, TSLP 
activates several immune cell subset, especially DCs, and induces Th2 differentiation and 
type 2 immunity in vitro and in vivo. 
TSLPR has low affinity for TSLP, but in combination with IL-7Rα generates a high-
affinity binding site for TSLP and triggers signaling through signal transducer and activator of 
transcription STAT1, STAT3, STAT5 and JAK1 and JAK2 (Figure 3) (1).  
However, freshly isolated human monocytes don’t express TSLPR complex. Human 
TSLPR and CD127 are co-expressed on monocytes only upon stimulation with LPS (Figure 
4) (10). 
1.3.1 TSLP as potential therapeutic target  
TSLP genetic variants and its dysregulated expression have been linked to atopic diseases 
(e.g. atopic dermatitis [AD], asthma), but also to other immune-mediated diseases such as 
cancer and rheumatoid arthritis (31). 
In approximately 10–60% of patients with B-cell acute lymphoblastic leukemias (ALL) 
and in some with T-ALL, there are somatic gain-of-function mutations in TSLP-R associated 
with the aberrant expression of TSLPRα and mutant CD127 proteins have formed a functional 
receptor TSLP (31,  32).  
Abnormally high expression of TSLP gene was observed in AD patients. Clinical trial 
assessing effectiveness of tezepelumab (AMG 157), a fully human anti-TSLP monoclonal 
antibody that specifically binds human TSLP preventing interaction with its receptor, in 
comparison to placebo in patients with severe AD has been completed (33).  
Tezepelumab also demonstrated improvements in lung function, and significantly reduced 
asthma exacerbations for patients with severe uncontrolled asthma (34). In addition, 
Tezepelumab reduced eosinophil counts and fractional exhaled nitric oxide concentrations 
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before allergen challenge, suggesting that TSLP is constitutively released in the airways of 
allergic asthmatic, and its blockade may provide similar clinical benefit to blockade of Th2 




2. Materials and methods 
2.1. Cell isolation and culture 
The study protocol involving the use of human blood cells was approved by the Ethics 
Committee of the University of Naples Federico II. Cells were isolated from buffy coats of 
healthy donors. Blood was layered onto Histopaque-1077 (Sigma-Aldrich) and mononuclear 
cells were collected at the interface. Monocytes were further purified with CD14 Microbeads 
(Miltenyi Biotec). Purity of cell preparations was > 95% as assessed by flow cytometry 
(CD14+ cells). Cells were cultured in cIMDM-5 (IMDM, 5% FCS, 1x non essential amino 
acids, 1x UltraGlutamine, 25 mM HEPES, 5 μ/ml gentamicin [Lonza]) in 96-well flat-bottom 
plates (105 monocytes/well) in a final volume of 250 μl. For experiments involving flow 
cytometry or fluorescence-activated cell sorting (FACS), cells were cultured in suspension 
(1.5 ml tubes for flow cytometry, 50 ml tubes for FACS) at a concentration not greater than 
2*106 cells/ml, then spun down and collected for the subsequent staining protocols. For 
experiments aimed at evaluating the modulation of TSLP receptor complex expression, cells 
were cultured in cIMDM-0.5 (0.5% FCS). 
Cells were treated with different combinations of: LPS (E. coli O26:B6) 10, 100 and 1000 
ng/ml, phytohemagglutinin (PHA) 10 µg/ml (Sigma), IL-4 10 ng/ml, TSLP 5 ng/ml (Miltenyi 
Biotec), anti-human TNF-α 1 µg/ml, mouse IgG1 κ isotype control 1 µg/ml (eBioscence), 
P3CSK4 10, 100 and 1000 ng/ml, Poly(I:C) 1 µg/ml, flagellin 10 ng/ml, imiquimod 1 µg/ml, 
ODN2006 1 µM, HKPA, HKSA and HKEB (monocytes:bacteria ratio 1:10) (Invivogen), 
BAY11-7082 0.5, 1 and 2 µM, SP600125 2 µM, CHIR-98014 200 nM, Wortmannin 1 µM 




Cytokine concentrations were measured in cell-free supernatants using commercially 
available ELISA kits for CCL17 (R&D Systems), TNF-α, IL-1β, IL-6 and IL-10 
(eBioscience). Briefly, 96-well plates (NUNC) were coated with capture antibody diluted in 
PBS. The plates were then washed in PBS containing 0.05% Tween-20 (PBST), and blocked 
with PBS+BSA 1%, before the incubation with standards and samples. The plates were then 
washed in PBST before incubation with the secondary antibody. The plates were then washed 
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in PBST before the addition of detection antibody. The plates were washed in PBST and 
Streptavidin-HRP was added. Then, the plates were washed in PBST before the addition of 
tetramethylbenzidine. The reaction was stopped with H2SO4 and a microplate reader (TECAN 
infinite 200 pro) was used to determine sample absorbance at 450 nM.  
Standard curves were generated with a Four Parametric Logistic curve fit and data were 
analysed using MyAssays Analysis Software Solutions (www.myassays.com). 
 
2.3. Flow and imaging cytometry 
Flow and imaging cytometry experiments were performed with purified monocytes. For 
surface staining, cells were stained (20 minutes at 4°C) in PBS + 10% human AB serum 
(Lonza) + 0.05% NaN3 (Staining buffer, SB). For phosphoprotein staining, cells were rested 
in cIMDM-0.5 for 1 hour and stimulated with the indicated cytokines for 15 minutes. Then, 
cells were fixed with paraformaldehyde (EM-grade, Electron Microscopy Sciences) (final 
concentration 1.5%) and permeabilized with absolute ice-cold methanol. Cells were stained 
(30 minutes at room temperature) in SB. The following antibodies were used: anti-human-
phospho-STAT5 AlexaFluor 647 (clone 47, dilution 1:20), anti-human-TSLPR APC (clone 
1A6, dilution 1:40) (BD Biosciences), anti-human-CD127 PE-Vio770 (clone MB15-18C9, 
dilution 1:20), anti-human-CD14 FITC (clone TÜK4, dilution 1:20), anti-human-CD16 PE 
(clone VEP13, dilution 1:20), anti-human-CD11b PE (clone M1/70.15.11.5, dilution 1:20), 
anti-human-CD11c PE (clone REA618, dilution 1:20), anti-human-HLA-DR PE (clone 
REA332, dilution 1:20), anti-human-CD1c PE (clone AD5-8E7, dilution 1:20) (Miltenyi 
Biotec). For flow cytometry experiments, samples were acquired on MACSQuant Analyzer 
10 (Miltenyi Biotec) and analyzed using FlowJo v10. Doublets, debris (identified based on 
forward and side scatter properties) and dead cells (identified with Zombie Violet Fixable 
Viability Kit [Biolegend]) were excluded from the analysis. Data are expressed as percentage 
of positive cells and median fluorescence intensity (MFI). For imaging cytometry 
experiments, samples were acquired on Amnis ImageStreamx Mark II (EMDMillipore). 
Unfocused cells and doublets were excluded from the analysis and representative images 




2.4. Fluorescence-activated cell sorting (FACS) 
For sorting of CD14hi CD16- and CD14+ CD16+ cells, monocytes were left untreated and 
stained with anti-CD14 and anti-CD16 antibodies. For sorting of TSLPR+ cells, monocytes 
were cultured for 14 hours as indicated above and then stained with anti-TSLPR. Staining 
were performed in PBS + 10% human AB serum (Lonza) for 30 minutes at 4°C, then cells 
were washed with PBS + 0.2% BSA, filtered (pre-separation filters [70 μm], Miltenyi Biotec) 
and sorted through a BD FACSARIA III (BD Biosciences). Purity of sorted cells was > 90%. 
The following antibodies were used to stain 20 – 30 x 106 monocytes: anti-human-TSLPR 
APC (clone 1A6, dilution 1:20) (BD Biosciences), anti-human-CD14 FITC (clone TÜK4, 
dilution 1:7), anti-human-CD16 PE (clone VEP13, dilution 1:8) (Miltenyi Biotec).  
 
2.5. Mixed leukocyte reaction (MLR) 
FACS-sorted TSLPR+ and TSLPR- monocytes were stimulated for 14 hours with LPS or 
LPS + IL-4 in cIMDM-5. Then, cells were washed and cultured in cIMDM-5 for 7 days with 
CD4+ T lymphocytes isolated with CD4 Microbeads (Miltenyi Biotec) from unrelated donors 
and labeled with CFSE (5 μM, Thermo-Fischer). Unstimulated and PHA-stimulated CD4+ T 
lymphocytes labeled with CFSE were used as controls. On day 7 non-adherent cells (i.e. 
CD4+ T lymphocytes) were harvested, acquired on a MACSQuant Analyzer 10 (Miltenyi 
Biotec) and analyzed using FlowJo v10. Doublets, debris (identified based on forward and 
side scatter properties) and dead cells (identified with Zombie Violet Fixable Viability Kit 
[Biolegend]) were excluded from the analysis. Unstimulated CFSE-labeled CD4+ T 
lymphocytes were employed to set the gate for CFSElow lymphocytes (i.e. proliferating 
lymphocytes). 
 
2.6. Time-lapse microscopy 
TSLPR+ and TSLPR- monocytes were stimulated for 14 hours with LPS or LPS + IL-4 in 
cIMDM-5. Over this time window digital phase contrast images of 15 fields/well were taken 
every 15 minutes with the Operetta High-Content Imaging System (PerkinElmer). To quantify 
cell movements, square displacement was calculated for each cell as the sum of squared 
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displacement of the X and Y axes. Then, the average of square displacements was calculated 
to compute the mean square displacement (MSD) for each condition.  
 
2.7. RNA isolation and real time RT-PCR 
Total RNA was extracted using TRIzol reagent (Invitrogen), according to the 
manufacturer’s protocol. For RNA-sequencing, RNA was extracted using ReliaPrep RNA 
Cell Miniprep System (Promega). Reverse transcription of 500 ng of total RNA was 
performed using SuperScript III Reverse Transcriptase (Invitrogen, Carlsberg, CA, USA), 
following the manufacturer’s instructions. Real time RT-PCR was performed in duplicate by 
using Universal SYBR Green Supermix (Bio-Rad) on CFX96 Real Time detection system 
(Bio-Rad). Relative quantification of gene expression was calculated by the ΔCt (relative 
expression x 104) method. Each Ct value was normalized to the respective ubiquitin C (UBC) 
Ct value. The following primer pairs were used: TSLPR forward 5’-ggtgacgtgttctgacctgt-3’; 
TSLPR reverse 5’-ttcctgtttggactgccact-3’; CCL17 forward 5’-tccagggatgccatcgttttt-3’; CCL17 
reverse 5’-tccctcactgtggctcttct-3’; TSLPR reverse ; GAS6 forward 5’- ctctctctgtggcactggtag -
3’; GAS6 reverse 5’-tatgctccacggccagga -3’ ; ALOX15B forward 5’-ctgagcaaggagcctggaga -
3’; ALOX15B reverse 5’-gctcatccggataggtgcc-3’; FCGR2B forward 5’actgagagtgactgggctga-t-
3’; FCGR2B reverse 5’-cacagctgtccacagaagca -3’; LAIR1 forward 5’-ccgtcggacaacagtcacaa-
3’; LAIR1 reverse 5’-aagaccactgagaccccgat-3’; MYC forward 5’-attctctgctctcctcgacg -3’; MYC 
reverse 5’-agcctgcctcttttccaca-3’; KLF4 forward 5’-agggagaagacactgcgtca-3’; KLF4 reverse 
5’-tcccgccagcggttattc-3’; PPARG forward 5’-aaaggcgagggcgatcttg -3’; PPARG reverse 5’-
gatggccacctctttgctct-3’; UBC forward 5’-ggtcgcagttcttgtttg -3’; UBC reverse 5’-
gatggtcttaccagtcaga-3’. 
 
2.8. RNA-sequencing and bioinformatic analysis 
The following samples were employed for next generation sequencing experiments: 3 pairs 
of TSLPR- and TSLPR+ mono, each pair obtained from a single donor. Next generation 
sequencing experiments, comprising samples quality control, were performed by 
Genomix4life S.R.L. (Baronissi, Salerno, Italy). Indexed libraries were prepared from 1 ug/ea 
purified RNA with TruSeq Stranded mRNA Sample Prep Kit (Illumina) according to the 
manufacturer’s instructions. Libraries were quantified using the Agilent 2100 Bioanalyzer 
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(Agilent Technologies) and pooled such that each index-tagged sample was present in 
equimolar amounts, with final concentration of the pooled samples of 2nM. The pooled 
samples were subject to cluster generation and sequencing using an Illumina HiSeq 2500 
System (Illumina) in a 2x100 paired-end format at a final concentration of 8pmol. The raw 
sequence files generated (.fastq files) underwent quality control analysis using FastQC 
(http://www.bioinformatics.babraham.ac.uk/projects/fastqc/, release 0.10.1). Raw reads were 
filtered and trimmed based on quality and adapter inclusion using Trimmomatic (release 0.35) 
(37).  
The human genome and gene annotation file (h38.83) were downloaded from EnsEMBL. 
First, the genome was indexed using STAR (release 2.5.0b)  (38). Then, filtered and trimmed 
reads were aligned on the genome. SAM output files from STAR were converted into BAM, 
sorted and indexed using the view, sort, index and programs from the SAMtools software 
collection (release 0.1.19-96b5f2294a)  (39).  
The gene annotation file has been collapsed into synthetic file using the 
createSyntheticTranscripts function from the easyRNASeq package (release 2.6.1) (40). This 
procedure has been performed to avoid counting reads multiple times by collapsing all 
existing transcripts of a single gene locus into a “synthetic” transcript containing every exon 
of that gene. The featureCounts program was used to count the number of reads overlapping 
genes (release 1.5.0-p1)  (41). All the genes not showing at least 1 read mapping per million 
mapped reads (CPM) in at least 2 samples were discarded. The bioconductor edgeR package 
(release 3.12.0) (42) was used to calculate the differential expression of genes between two 
conditions. This package measures the significance of the variation in expression levels using 
the dispersion of the expression levels among sample replicates. According to the comparison, 
significantly up/downregulated genes were sorted based on the p value. The top 500 
differentially expressed genes (DEGs) (p ≤ 0.05) were used to perform Gene Ontology (GO) 
enrichment analysis using DAVID tool (release 6.7) (43). Their expression levels were 
represented in the heatmap using MeV software (multi-experiment viewer – v4.8.1) (44). 
 
2.9. Accession number 





2.10. Statistical analysis 
Statistical analysis was performed with Prism 6 (GraphPad Software). p values were 
calculated with two-tailed paired t test, repeated measure one-way or two-way ANOVA 
corrected for multiple comparisons, or Wilcoxon matched-pairs signed rank test as indicated 





3.1 TSLP enhances human monocyte production of CCL17 
We have recently shown that the STAT5-activating cytokines IL-3 and GM-CSF synergize 
with the STAT6-activating cytokine IL-4 to enhance human monocyte production of CCL17 
(14). Since TSLP also activates STAT5 (2), we stimulated monocytes with TSLP and IL-4 for 
21-24 hours in the absence or presence of LPS, which induces monocyte expression of TSLPR 
and CD127 mRNAs (10), and assessed the production of CCL17. In the absence of LPS only 
low levels of CCL17 could be detected. CCL17 production could not be detected when 
monocytes were stimulated with TSLP in the presence or absence of LPS (which is consistent 
with the absence of myeloid DCs in our monocyte preparations). Interestingly, the addition of 
TSLP to LPS and IL-4 significantly enhanced CCL17 production (Figure 5A). Comparable 
results were obtained when monocytes were primed with LPS for 14 hours and then 
stimulated for 21-24 hours with IL-4 and TSLP in the presence or absence of LPS 
(Supplementary Figure 1A). To better characterize the effects of TSLP on monocyte 
activation, we evaluated the production of TNF-α, IL-1β, IL-6 and IL-10 upon stimulation 
with IL-4 and TSLP in the presence of LPS. However, none of these cytokines was 
significantly modulated by TSLP (Figure 5B). Thus, human monocyte activation with TSLP 
specifically enhances IL-4-induced CCL17 production in the presence of LPS. 
 
3.2. TLR4 activation elicits a subset of human TSLPR+ monocytes that preferentially 
originates from CD16- monocytes 
Since TSLP is able to modulate monocyte production of CCL17, we then looked for the 
surface expression of TSLP receptor complex subunits (TSLPR and CD127) by flow 
cytometry. Freshly isolated monocytes did not express TSLPR and CD127, nor did they 
phosphorylate STAT5 in response to TSLP (data not shown). Critically, stimulation of 
monocytes for 14 hours with LPS induced the expression of TSLP receptor complex subunits 
on a small percentage of monocytes (TSLPR+ mono), while the vast majority expressed only 
CD127 without TSLPR or neither of them (TSLPR- mono) (Figure 6A). We confirmed by 
imaging cytometry that TSLPR and CD127 co-localize on the surface of TSLPR+ mono 
(Figure 6C). Accordingly, when monocytes were pre-treated with LPS and then stimulated 
with TSLP for 15 minutes, a comparable percentage of monocytes phosphorylated STAT5 
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(pSTAT5+ cells) (Figure 6B), indicating that LPS pre-treatment induced the expression of a 
functional TSLP receptor complex only on a small subset of monocytes. 
Next, we sought to characterize whether TLR agonists other than LPS (which is a TLR4 
agonist) elicit TSLPR+ mono. To this aim, monocytes were pre-treated with LPS (TLR4 
agonist), P3CSK4 (TLR2 agonist), Poly(I:C) (TLR3 agonist), flagellin (TLR5 agonist), 
imiquimod (TLR7 agonist) or ODN 2006 (TLR9 agonist), and then we assessed the 
expression of TSLPR and CD127 or pSTAT5 in response to TSLP. TLR4 activation induced 
the highest percentage of TSLPR+ mono (Figure 6D), although higher concentrations of the 
TLR2 agonist P3CSK4 also induced TSLPR+ mono (Supplementary Figure 1B). 
Interestingly, TSLPR+ mono were also elicited by heat-killed Gram-negative bacteria 
(Pseudomonas aeruginosa [HKPA] and Escherichia coli O111:B4 [HKEB]), while the heat-
killed Gram-positive bacterium Staphylococcus aureus (HKSA) had a negligible effect on 
TSLPR and CD127 surface expression (Figure 6E). 
Human monocytes can be divided into classical, intermediate and non-classical monocytes 
based on their expression of CD14 and CD16 (CD14hi CD16-, CD14+ CD16+ and CD14dim 
CD16+, respectively) (45), although other markers have been proposed to distinguish these 
subsets (46). The majority of monocytes in our preparations (which were isolated based on 
CD14 expression) had a CD14 hi CD16- phenotype (classical monocytes), while only a small 
percentage had a CD14+ CD16+ phenotype (intermediate monocytes) and virtually no 
CD14dim CD16+ (non-classical) monocytes (Supplementary Figure 1C, left panel). To 
assess the ontogeny of TSLPR+ mono, we FACS-sorted CD14hi CD16- and CD14+ CD16+ 
monocytes and stimulated them with LPS before assessing TSLPR surface expression. Only a 
small percentage of CD14+ CD16+ monocytes became TSLPR+ (Supplementary Figure 1C, 
right panel). Since most of the monocytes in our preparations were CD16-, it is likely that 
TSLPR+ mono preferentially originated from this subset with a rather minor contribution of 
CD14+ CD16+ monocytes. 
 
3.3. TLR4-activated signaling pathways required for the induction of TSLPR+ 
monocytes 
Pro-inflammatory and infectious stimuli induce the expression of TSLP receptor complex 
as well as its ligand TSLP in epithelial cells (47-49). However, the expression of TSLP receptor 
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complex in this model is not mediated by nuclear factor NF-κB, since overexpression of the 
NF-κB subunits p50 and p65 does not induce TSLP receptor complex, nor does the inhibitor 
BAY 11-7082 (which inhibits TNF-α-induced IκBα phosphorylation and thus NF-κB nuclear 
translocation) impair its expression. On the contrary, both approaches affect TSLP expression 
(48). To evaluate the contribution of NF-κB to the expression of TSLP receptor complex in our 
model, we stimulated monocytes with LPS in the presence of different concentrations of BAY 
11-7082. Interestingly, BAY 11-7082 concentration-dependently reduced the percentage of 
TSLPR+ mono (Figure 7A). Since TNF-α induces TSLP receptor complex expression in 
epithelial cells and human hematopoietic progenitors (47, 50), we also evaluated the contribution 
of LPS-induced autocrine TNF-α to TSLP receptor expression. The addition of an anti-TNF-α 
blocking antibody to LPS did not significantly modify the percentage of TSLPR+ mono 
(Supplementary Figure 2A), thus ruling out any role for TNF-α in our model. TLR4 also 
signals through MAPKs (i.e. ERK1/2, p38, JNK) (51), which may be involved in the 
modulation of TSLP receptor complex. Indeed, the p38 inhibitor SB203580 reduced (Figure 
7B), while inhibitors of MEK1/2 (U0126, which in turn inhibits ERK1/2) and JNK 
(SP600125) had no effect on the percentage of TSLPR+ mono (Supplementary Figure 2B). 
LPS-mediated TLR4 activation triggers the PI3K/Akt pathway, which exerts anti-
inflammatory properties at least in part by restraining NF-κB and GSK-3 pro-inflammatory 
activities (51). Since the TLR4-mediated monocyte pro-inflammatory activation is required for 
eliciting TSLPR+ mono, we evaluated the role of PI3K in our model. The PI3K inhibitors 
wortmannin and LY294002 markedly increased the percentage of TSLPR+ mono. To test the 
balance between PI3K and GSK-3, we employed the GSK-3 inhibitor CHIR-98014. 
Interestingly, CHIR-98014 alone did not modulate the percentage of TSLPR+ mono. 
However, when CHIR-98014 was administered along with the PI3K inhibitors it completely 
reverted their effect, since the percentage of TSLPR+ mono in these conditions was 
comparable to that of monocytes stimulated with LPS without any inhibitors (Figure 7C). 
 
3.4. TSLPR+ monocytes exhibit discrete phenotypic and functional features 
The results obtained so far support a model in which the balance between intracellular pro-
inflammatory (e.g. NF-κB, p38, GSK-3) and anti-inflammatory (e.g. PI3K) pathways 
activated by LPS dictates the emergence of TSLPR+ mono. We next decided to characterize 
the phenotypic and functional features of TSLPR+ and TSLPR- mono. First, we evaluated the 
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surface expression of the myeloid cell markers CD14, CD11b and CD11c. Although they 
were expressed by both subsets, TSLPR+ mono exhibited higher levels of CD11c, and lower 
levels of CD14 and CD11b (Supplementary Figure 2C). Then, we assessed the response of 
TSLPR+ and TSLPR- mono to LPS, IL-4 and TSLP. Monocytes were pre-treated for 14 hours 
with LPS, FACS-sorted into TSLPR+ and TSLPR- mono and stimulated for 16-18 hours in the 
presence of LPS without or with IL-4, TSLP or a combination of them. Interestingly, TSLPR 
mRNA was expressed by TSLPR+ mono while it was not induced in TSLPR- mono under any 
of the tested conditions (Figure 8A), suggesting that once the distinction between these 
subsets is established during LPS pre-treatment it remains stable. We also assessed CCL17 
mRNA levels and surprisingly we found that only TSLPR+ mono expressed CCL17 in 
response to IL-4 (Figure 8B), despite both subsets phosphorylated STAT6 in response to IL-4 
(data not shown) and TSLPR+ mono did not express higher levels of transcription factors 
involved in monocyte/macrophage alternative activation (i.e. MYC, KLF4, PPARG) 
(Supplementary Figure 2D) (52-55). These results were confirmed by evaluating CCL17 
protein levels in cell-free supernatants (Figure 8C). To account for possible cross-talks 
between TSLPR+ mono and TSLPR- mono that could result in the expression of CCL17 also 
in the TSLPR- subset, monocytes were pre-treated with LPS and IL-4 and FACS-sorted 
TSLPR+ and TSLPR- mono were directly harvested for RNA isolation without further re-
stimulation. In keeping with our previous results, the expression of TSLPR and CCL17 
mRNAs was higher in the TSLPR+ subset (Figure 8D). To further characterize the response 
of TSLPR+ and TSLPR- mono we evaluated the production of TNF-α, IL-1β, IL-6 and IL-10, 
and found that in each of the tested conditions TSLPR+ mono produced respectively lower 
and higher levels of IL-6 and IL-10. TSLPR+ mono showed reduced TNF-α production only 
when stimulated with LPS and TSLP, while no significant differences in the production of IL-
1β were observed (Figure 8E). 
These results support the concept of an LPS-induced functional specialization in an 
apparently homogeneous population of human CD14+ monocytes. To gain further insights 
into this model, we performed a transcriptomic analysis of FACS-sorted TSLPR+ and TSLPR- 
mono re-stimulated with LPS for 14 hours. Gene ontology (GO) analysis revealed distinct 
enrichment for biological processes between TSLPR- and TSLPR+ mono (Figure 9A, 9B). 
Moreover, these cell subsets also exhibited different gene expression profiles (Figure 10). 
Unexpectedly, TSLPR+ mono expressed higher levels of CD1C, a marker of DCs (56, 57) 
assigned to the conventional DC 2 (cDC2) lineage (58), and also of genes that are commonly 
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associated with antigen processing and presentation (e.g. LAMP3, MHC class II genes) 
(Supplementary Tables I, II). These results are consistent with the increased surface 
expression of HLA-DR (Figure 11A). We also confirmed the surface expression of CD1c in 
TSLPR+ mono, while it was not expressed by TSLPR- mono (Figure 11B). Since one of the 
main features of DCs is antigen presentation and the ability to induce T cell proliferation, we 
challenged TSLPR+ and TSLPR- mono (re-stimulated for 14 hours with LPS or LPS and IL-4) 
with CFSE-labeled CD4+ T lymphocytes isolated from an unrelated donor. TSLPR+ mono re-
stimulated with LPS were the most efficient in promoting T cell proliferation, although the 
overall proliferation rate was low and consistent with the monocytic origin of these cells 
(Figure 11C). GO analysis also revealed enrichment for genes associated with cell motility in 
TSLPR+ mono (Figure 9B). To corroborate these findings, we performed time-lapse 
microscopy of TSLPR+ and TSLPR- mono re-stimulated as indicated above. TSLPR+ mono 
displayed increased cell motility and mean square displacement (MSD) (Figure 11D) in cell 
tracking experiments. Finally, we confirmed that TSLPR+ mono re-stimulated with LPS or 
LPS and IL-4 expressed higher levels of genes with important immune functions (Figure 12): 
GAS6, ligand of the TAM receptor AXL that exerts several functions including promoting 
tumor growth (59); ALOX15B, an enzyme involved in the synthesis of pro-resolving lipid 
mediators (60); FCGR2B and LAIR1, inhibitory receptors that bind respectively the constant 
region of IgG and collagen or collagen-like motif-containing proteins (e.g. C1q and surfactant 
protein D) (61, 62). 
 
3.5. TSLPR is preferentially expressed by a subset of CD14+ CD1c+ monocytes 
The evidence of increased CD1c expression among TSLPR+ mono was rather unexpected 
since CD1c is commonly considered a surface marker of cDC2 (56, 57). Thus, we decided to 
investigate the expression of CD1c in our preparations of CD14+ monocytes by flow 
cytometry. Surprisingly, we found that approximately 1% of monocytes in our preparations 
exhibited a CD14+ CD1c+ phenotype. Comparable results were obtained with LPS-stimulated 
monocytes (Figure 13A). Of note, the majority of CD14+ CD1c+ monocytes expressed 
TSLPR upon LPS stimulation, although TSLPR was also expressed by a small percentage of 
CD14+ CD1c- that may significantly contribute to the population TSLPR+ mono owing to the 
high number of CD14+ CD1c- cells in our preparations (Figure 13B). Nevertheless, LPS-
17 
 
stimulated CD14+ CD1c+ monocytes expressed the highest levels of TSLPR as assessed on 
total CD14+ CD1c+ (Figure 13C, 13D) or CD14+ CD1c+ TSLPR+ cells (Figure 13E). 
 
3.6. In vivo monocyte expression of TSLPR and CD127 in Gram-negative sepsis 
So far we have characterized the signals that elicit TSLPR+ mono and the phenotypic and 
functional properties of this subset in vitro. To evaluate the in vivo relevance of our findings, 
we took advantage of public available microarray (GSE46955) performed on human CD14+ 
monocytes isolated from patients with a diagnosis of Gram-negative sepsis (blood culture 
positive for Escherichia coli) and after their complete recovery (i.e. 1-3 months after 
resolution), as well as healthy control (63). By analysing these data we found that monocytes 
isolated from patients with Gram-negative sepsis expressed increased levels of TSLPR and 
CD127 mRNAs compared to healthy controls (Figure 14A). Interestingly, expression levels 
of both genes were reduced after recovery (Figure 14B), likely linking monocyte expression 





The starting point of our investigation was the responsiveness of human CD14+ monocytes 
to TSLP. Although we demonstrate that TSLP modulates CCL17 production, we have not 
fully characterized its effects on human monocytes, nor have we identified a specific response 
elicited by TSLP alone in the absence of IL-4. Instead, we decided to focus our attention on 
the characterization of TSLPR+ mono, which was an unexpected yet interesting aspect of our 
study. The identification of TSLPR+ mono may also contribute to a deeper understanding of 
human monocyte responsiveness to TSLP, since it raises the question of whether TSLPR+ 
mono are the sole monocyte subset that can be activated by TSLP. Even more importantly, 
LPS induces TSLPR expression on the majority of CD14+ monocytes that co-expresses the 
myeloid DC marker CD1c. TSLPR expression on this subset of CD14+ CD1c+ monocytes is 
higher compared to CD14+ CD1c- cells. Thus, the population of TSLPR+ mono is composed 
of CD14+ CD1c+ and CD14+ CD1c- monocytes, and it is tempting to speculate that some if 
not most of the properties we have identified for TSLPR+ mono may actually be ascribed to 
CD14+ CD1c+ cells. Nevertheless, the percentage of TSLPR+ mono is not only reduced by 
NF-κB and p38 inhibitors, but is also increased by PI3K inhibitors via activation of GSK-3. 
These results highlight a complex network of intracellular pathways that regulates TSLPR 
expression and also argue against the hypothesis that TSLPR+ mono derive solely from pre-
committed precursors. Indeed, it would be unlikely to increase the percentage of TSLPR+ 
mono using PI3K inhibitors if this subset originated exclusively from pre-committed 
precursors. It is conceivable that TSLPR+ mono also emerge from LPS-stimulated CD14+ 
CD1c- monocytes through a stochastic process dictated by the intracellular balance between 
pro-inflammatory (e.g. NF-κB, p38, GSK-3) and anti-inflammatory (e.g. PI3K) pathways. 
Once this intracellular balance has been established, it is likely to influence subsequent 
responses of TSLPR+ and TSLPR- mono. For example, re-stimulation of TSLPR- mono does 
not induce TSLPR expression. Moreover, it would be interesting to evaluate whether such 
modulation of signaling pathways also promotes the conversion of CD14+ CD1c- toward 
CD14+ CD1c+ monocytes. Interestingly, studies performed at the single cell level have 
revealed, in contrast to population-level studies, a remarkable heterogeneity in the activation 
of signaling pathways and gene expression programs upon stimulation of apparently 
homogeneous populations (65-66). Moreover, it is now clear that even innate immune cells 
preserve memory of their previous stimulation (67, 68). Further studies are required to 
understand the relative contribution of pre-committed CD14+ CD1c+ progenitors and their 
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relationship to CD14+ CD1c- monocytes as well as stochastic differences in the activation of 
signaling pathways to the emergence of TSLPR+ mono. 
The existence of CD14+ CD1c+ cells (referred to as human inflammatory DCs, infDCs) has 
been reported in several inflammatory conditions, including ovarian and breast tumor ascites 
(69). infDCs induce higher CD4+ T cell proliferation and Th17 skewing compared to CD14+ 
CD16+ CD1c- inflammatory macrophages isolated from the same tissue, probably due to their 
ability to produce the Th17-polarizing cytokine IL-23 (70). While this manuscript was in 
preparation, the presence of CD14+ CD1c+ monocytes has been reported in the peripheral 
blood of healthy donors and mucosal tissues isolated from distal duodenum/proximal jejunum 
of pancreatic cancer patients, nasal mucosa of healthy donors or allergic patients, or bronchial 
mucosa obtained from patients with non-small cell lung carcinoma (71). Importantly, the 
frequency of this subset is elevated in the peripheral blood of stage III or IV melanoma 
patients and in skin melanoma lesions compared to healthy donors (72). CD14+ CD1c+ cells are 
less efficient at inducing CD4+ T cell proliferation compared to CD1c+ DCs (suggesting their 
classification as monocytes) (71, 72) and also exhibit a unique gene signature (72). We 
demonstrate that CD14+ CD1c+ cells express higher levels of TSLPR in response to LPS 
compared to CD14+ CD1c- monocytes. Interestingly, TSLP promotes myeloid DC maturation, 
cytokine production and their ability to induce CD4+ T cell proliferation and polarization 
toward distinct phenotypes (e.g. Th1, Th2, Th17) depending on the inflammatory milieu. It 
will be interesting to evaluate whether TSLP exerts similar effects on CD14+ CD1c+ cells. 
Indeed, it is likely that this monocyte subset is the most responsive to TSLP. Further studies 
are warranted to assess the spectrum of responses elicited by TSLP in CD14+ CD1c+ TSLPR+ 
cells.  
Among the list of differentially expressed genes we confirmed that TSLPR+ mono express 
higher levels of gene with important immune-related functions: GAS6, ALOX15B, FCGR2B 
and LAIR1. GAS6 encodes the vitamin K-dependent protein GAS-6 that is mainly produced 
by endothelial cells, vascular smooth muscle cells and hematopoietic cells. It binds the TAM 
receptor tyrosine kinases, especially AXL, and as such is involved in the regulation of 
inflammation, promotes tissue repair and vascular homeostasis, and modulates both cancer 
cell growth and tumor-associated immune cell functions (59). Of note, tumor cells promote 
GAS-6 production by tumor-associated macrophages that in turn promote cancer growth and 
metastasis (73). ALOX15B encodes the enzyme arachidonate 15-lipoxygenase B (15-LOX-B) 
that mainly catalyzes the conversion of arachidonate into 15(S)-HpETE, which is in turned 
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converted to 15(S)-HETE that acts as a precursor for the synthesis of the pro-resolving lipid 
mediators lipoxins (60). FCGR2B encodes the only receptor (FcγRIIB) for the constant region 
of IgG endowed with inhibitory properties (61). LAIR1 encodes an inhibitory receptor (LAIR-1 
or CD305) for collagen or collagen-like motif-containing proteins (e.g. C1q and surfactant 
protein D). Its activation impairs monocyte cytokine production and differentiation toward 
DCs (62, 74-76). Considering these results with the increased production of CCL17 and IL-10 
and the lower production of IL-6 by TSLPR+ mono, it is tempting to speculate that this subset 
is endowed with immunoregulatory/anti-inflammatory properties. Again, whether these 
properties belong to CD14+ CD1c+ TSLPR+ cells, CD14+ CD1c- TSLPR+ cells or both subsets 
remains to be established. 
In conclusion, by investigating human CD14+ monocyte responsiveness to TSLP we 
unravel a previously unknown phenotypic and functional heterogeneity marked by differential 
TSLPR expression. The expression of the myeloid DC marker CD1c within the TSLPR+ 
mono subset revealed further heterogeneity. Indeed, peripheral blood monocytes can be 
divided into CD14+ CD1c- and CD14+ CD1c+ cells, the latter expressing the highest levels of 
TSLPR upon LPS stimulation. Considering the increased expression of TSLPR mRNA in 
CD14+ monocyte isolated from patients with Gram-negative sepsis, the expansion of CD14+ 
CD1c+ cells in the peripheral blood of melanoma patients and their unique gene expression 
signature, further efforts should be made to characterize the functional properties of this 
subset (e.g. responsiveness to TSLP), its relationship to CD14+ CD1c- monocytes and cDC2 




5. Figure legends 
 
From Dranoff G. 2004. Nature Reviews Cancer. 4: 11-22 
Figure 1. The innate immune response functions as the first line of defence against infection. It 
consists of soluble factors, such as complement proteins, and diverse cellular components including 
granulocytes (basophils, eosinophils and neutrophils), mast cells, macrophages, dendritic cells and 
natural killer cells. The adaptive immune response is slower to develop, but manifests as increased 
antigenic specificity and memory. It consists of antibodies, B cells, and CD4+ and CD8+ T 
lymphocytes. Natural killer T cells and  T cells are cytotoxic lymphocytes that straddle the 






Adapted from Ziegler-Heitbrock L. 2010 Blood 116: 74-80 







From Ziegler SF 2012 J Allergy Clin Immunol 130: 845-52 
Figure 3. Schematic representation of the TSLP receptor complex. Schematic of TSLP bound by the 
TSLP receptor. JAK1 and JAK2, as well as the STAT proteins shown to be activated following 







From Reche P. A. 2001 The Journal of Immunology 67: 336-343 
Figure 4. Expression profiles of TSLPR and IL-7Ra. Expression of TSLPR and IL-7Ra was measured 
by quantitative PCR on a panel of human (h) cDNA libraries made from various tissues and cell types. 
Cells were often left untreated or were treated with different stimuli as indicated before RNA was 
isolated. Expression levels were normalized and expressed as femtograms per 50 ng total cDNA. 
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Figure 5. TSLP enhances LPS and IL-4-induced CCL17 production (A and B). Human CD14+ 
monocytes were stimulated with IL-4 and TSLP in the absence or presence of LPS for 21-24 hours. 
CCL17, TNF-α, IL-1β, IL-6 and IL-10 levels were assessed by ELISA in cell-free supernatants. Data 
are shown as mean + SEM of 11 (A) or 8 (B) independent experiments. * p < 0.05 determined by 
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Figure 6. LPS stimulation elicits a subset of TSLPR+-expressing 
monocytes (TSLPR+ mono). (A, B, D, E) Human CD14+ monocytes were stimulated with LPS (A, 
B), several TLR agonists (D) or heat-killed bacteria (E) for 14 hours and the percentages of TSLPR+ 
CD127+ cells (TSLPR+ mono) (A, D, E) or pSTAT5+ cells in response to TSLP (B, D) were assessed 
by flow cytometry. A representative contour plot of TSLPR and CD127 expression is shown in A, left 
panel. (C) Cells were treated as in A and the expression and co-localization of TSLPR and CD127 
were assessed in TSLPR+-mono (upper panel) or TSLPR- mono (lower panel) by imaging cytometry. 
A representative cell for each subset is shown. Data are shown as mean + SEM of 9 (A, B), 4 (D) or 6 
(E) independent experiments. * p < 0.05, ** p < 0.01 determined by two-tailed paired t test (A, B) and 
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Figure 7. Signaling pathways required for TSLPR+-mono emergence. (A-C) Human CD14+ 
monocytes were stimulated with LPS in the presence or absence of BAY 11-7082 (NF-κB inhibitor) 
(A), SB203580 (p38 inhibitor) (B), wortmannin, LY294002 (PI3K inhibitors) and CHIR-98014 (GSK-
3 inhibitor) (C) for 14 hours and the percentages of TSLPR+ CD127+ cells (left panels) or pSTAT5+ 
cells in response to TSLP (right panels) were assessed by flow cytometry. Data are shown as mean + 
SEM of 5 (A) or 6 (B, C) independent experiments. * p < 0.05, ** p < 0.01 determined by repeated 
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Figure 8. TSLPR+ mono display a different cytokine profile. (A-E) Human CD14+ monocytes were 
pre-treated with LPS (A-C, E) or LPS + IL-4 (D) for 14 hours and FACS-sorted into TSLPR- and 
TSLPR+ mono. Then, cells were directly harvested for RNA isolation and real time RT-PCR analysis 
(D) or further stimulated with LPS, IL-4 and TSLP for 16-18 hours (A-C, E). Cytokine levels were 
assessed in cell-free supernatants by ELISA (C, E) and cells were harvested for RNA isolation and real 
time RT-PCR analysis (A, B). Black bars, TSLPR- mono. White bars, TSLPR+ mono. Data are shown 
as mean + SEM of 4 (A-C, E), or 2 (D) independent experiments. * p < 0.05, ** p < 0.01 determined 














Figure 9. Transcriptomic analysis of TSLPR- and TSLPR+ mono re-stimulated with LPS. (A, B) Pie-
charts show the top ten biological functions by the 178 (A) and 322 (B) genes upregulated in TSLPR- 
and TSLPR+ human monocytes, respectively. The colour gradient indicates the GO terms ordered 









Figure 10. Transcriptomic analysis of TSLPR- and TSLPR+ mono re-stimulated with LPS. 
Hierarchical clustering of the top 500 genes (rows) based on their relative expression levels in each 
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Figure 11. TSLPR+ mono exhibit different phenotypic and functional properties. (A, B) Human 
CD14+ monocytes were stimulated with LPS for 14 hours and the expression of (A) HLA-DR and (B) 
CD1c was assessed by flow cytometry as median fluorescence intensity (MFI). Lower panels, 
representative histograms of (A) HLA-DR and (B) CD1c expression in TSLPR- and TSLPR+ mono. 
(C) Human CD14+ monocytes were pre-treated with LPS for 14 hours and FACS-sorted into TSLPR+ 
and TSLPR- mono. (C) Cells were stimulated with LPS or LPS + IL-4 for 14 hours, washed and then 
cultured with CFSE-labeled CD4+ T lymphocytes isolated from unrelated donors for 7 days. 
Unstimulated (CTRL) and phytohemagglutinin-stimulated (PHA) lymphocytes were used as controls. 
The percentage of CFSElow (i.e. proliferating) cells was assessed by flow cytometry. (D) Cells were 
stimulated with LPS or LPS + IL-4 for 14 hours and digital phase contrast images were taken every 15 
minutes with a 20x objective. Cell movements were expressed as mean square displacement (MSD, 
mean squared distance between cell positions at the end and at the beginning of the cell-tracking 
experiment). Data are shown as mean + SEM (A-D) of 6 (A, B), 3 (C) or 4 (D) independent 
experiments. * p < 0.05,   ** p < 0.01 determined by two-tailed paired t test (A, D), repeated measure 
two-way ANOVA with Sidak’s post hoc test (B), repeated measure one-way ANOVA with Tukey’s 
post hoc test (C) . 
  










































































































































































































































































































































































































































Figure 12.  TSLPR+ mono exhibit different phenotypic and functional properties. Cells were 
stimulated with LPS or LPS+IL-4 for 14 hours and then harvested for RNA isolation and subsequent 
real time RT-PCR analysis. Data are shown as the median, the 25th and 75th percentiles (boxes) and 
the 5th and 95th percentiles (whiskers) of 6 independent experiments. * p < 0.05 determined by 
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Figure 13. TSLPR+ mono exhibit different phenotypic and functional properties. (A) Human 
peripheral blood or LPS-stimulated CD14+ monocytes were stained for CD14 and CD1c, and the 
percentages of CD1c- and CD1c+ among CD14+ cells were calculated. Right panels, representative 
contour plots. (B-E) Human CD14+ monocytes were stimulate with LPS and stained for CD14, CD1c 
and TSLPR. Percentage of TSLPR+ cells and TSLPR MFI were calculated in the indicated 
populations. (D) Representative histograms of TSLPR expression in unstained controls, CD14+ CD1c- 
and CD14+ CD1c+ cells. Data are shown as mean + SEM (A-C, E) of 6 (A-C, E) independent 
experiments. * p < 0.05, ** p < 0.01 determined by two-tailed paired t test (B, C, E), repeated measure 
two-way ANOVA with Sidak’s post hoc test (A).  



























               













































               






















Figure 14. In vivo expression of TSLPR and CD127 mRNAs. (A, B) Public available microarray 
(GSE46955) performed on peripheral blood human CD14+ monocytes isolated from patients during 
Gram-negative sepsis (Sepsis, n=7) (A, B) and following their resolution or recovery (Recovery, n=7) 
(B) as well as from healthy donors (Healthy, n=5) (A) were analysed to assess TSLPR and CD127 
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Supplementary Figure 1. (A) Human CD14+ monocytes were pre-treated with LPS for 14 hours and 
then stimulated for 21-24 hours with IL-4 and TSLP in the presence or absence of LPS. CCL17 levels 
were assessed by ELISA in cell-free supernatants. (B) CD14+ human monocytes were stimulated with 
increasing concentrations (10, 100 and 1000 ng/ml) of LPS and P3CSK4 for 14 hours and the 
percentages of TSLPR+ CD127+ cells or pSTAT5+ cells in response to TSLP were assessed by flow 
cytometry. (C) Human CD14+ monocytes were sorted into CD14hi CD16- and CD14+ CD16+ and 
then stimulated overnight with LPS. The expression of TSLPR was assessed by flow cytometry. 
Numbers above bars represent means. Data are shown as mean + SEM of 21 (A), 6 (B) or 4 (C) 
independent experiments. * p < 0.05, ** p < 0.01 determined by repeated measure one-way ANOVA 
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Supplementary Figure 2  (A, B) Human CD14+ monocytes were stimulated with LPS in the 
presence or absence of αTNF-α (a blocking anti-TNF-α antibody) or an isotype control (Iso) (A), 
U0126 (MEK1/2 inhibitor) and SP600125 (JNK inhibitor) (B) for 14 hours and the percentages of 
TSLPR+ CD127+ cells or pSTAT5+ cells in response to TSLP were assessed by flow cytometry. (C) 
Human CD14+ monocytes were stimulated with LPS for 14 hours and the expression of CD14, 
CD11b and CD11c was assessed by flow cytometry as median fluorescence intensity (MFI). (D) 
Human CD14+ monocytes were pre-treated with LPS for 14 hours, FACS-sorted into TSLPR+ and 
TSLPR- mono and stimulated with LPS or LPS+IL-4 for 14 hours. Then, cells were harvested for 
RNA isolation and subsequent real time RT-PCR analysis. Data are shown as mean + SEM of 3 (A), 5 
(B) or 6 (C) independent experiments, or as the median, the 25th and 75th percentiles (boxes) and the 
5th and 95th percentiles (whiskers) of 6 independent experiments. (Figure legend continues)  
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Statistical significance was determined by repeated measure one-way ANOVA with Tukey’s post hoc 




  Supplementary Table I 
Upregulated gene transcripts in TSLPR- vs TSLPR+ 
Gene_Symbol Ensembl_ID logFC PValue FDR TSLPR- 1 TSLPR- 2 
SMAD3 ENSG00000166949 -3.11290 1.44E-05 0.007947 5.75806 2.28999 
MYO10 ENSG00000145555 -1.85405 3.08E-05 0.013257 66.68877 31.16027 
PPARG ENSG00000132170 -2.31776 3.28E-05 0.013429 21.46185 5.64320 
CARD16 ENSG00000204397 -1.38768 0.000219 0.04891 104.79664 45.06380 
HS3ST2 ENSG00000122254 -3.63827 0.00027 0.058194 3.45483 0.24536 
SNAPC1 ENSG00000023608 -1.74133 0.000472 0.084448 108.35617 25.84421 
MMP10 ENSG00000166670 -2.97568 0.000503 0.087499 1127.63697 43.01916 
CDCP1 ENSG00000163814 -1.92211 0.000549 0.092975 107.62332 14.63960 
IGFN1 ENSG00000163395 -2.41703 0.000568 0.093775 128.66640 18.97423 
CCND1 ENSG00000110092 -2.53959 0.000674 0.104056 15.28502 1.55392 
GPRC5C ENSG00000170412 -1.80167 0.00068 0.104056 10.36450 5.39784 
CCDC17 ENSG00000159588 -1.70772 0.000925 0.127779 22.29938 7.44248 
ZEB1 ENSG00000148516 -3.23303 0.001051 0.137245 15.18033 0.57250 
NDRG4 ENSG00000103034 -3.43521 0.001204 0.151564 1.36100 0.32714 
OLIG2 ENSG00000205927 -1.58629 0.001376 0.168187 47.42545 21.83672 
AEN ENSG00000181026 -1.92216 0.001508 0.175823 78.10019 14.63960 
RGS17 ENSG00000091844 -3.21136 0.001543 0.177988 1.36100 0.16357 
SPINK1 ENSG00000164266 -1.80693 0.001635 0.185477 203.62584 53.48770 
NCOR2 ENSG00000196498 -1.24418 0.00165 0.185559 321.19490 157.27347 
CD244 ENSG00000122223 -2.77480 0.002041 0.22166 16.22725 1.63571 
CD109 ENSG00000156535 -1.45169 0.002097 0.225877 163.42413 112.20967 
DUSP16 ENSG00000111266 -2.08920 0.002184 0.228057 150.65171 24.94457 
SH2D5 ENSG00000189410 -4.31300 0.002425 0.238898 3.14076 0.08179 
PLPP3 ENSG00000162407 -1.93046 0.002551 0.24564 185.30475 27.64349 
WHRN ENSG00000095397 -1.58704 0.002829 0.266053 9.73635 4.98891 
SYPL2 ENSG00000143028 -2.02654 0.002897 0.268701 2.30322 1.47214 
AICDA ENSG00000111732 -3.23756 0.003166 0.28475 0.52346 0.24536 
TFPI2 ENSG00000105825 -3.13477 0.00331 0.28475 1222.80195 18.64709 
EML5 ENSG00000165521 -2.38189 0.003265 0.28475 1.46569 0.73607 
TNFSF8 ENSG00000106952 -2.33990 0.003194 0.28475 6.17682 2.37178 
KCNJ14 ENSG00000182324 -2.29357 0.003274 0.28475 2.40791 0.81785 
HIVEP3 ENSG00000127124 -2.48800 0.003746 0.307454 51.08967 3.68035 
ADAMTSL4-
AS1 
ENSG00000203804 -2.33114 0.003772 0.307454 7.11905 1.96285 
DNHD1 ENSG00000179532 -1.19570 0.003774 0.307454 52.66005 26.25314 
HCAR2 ENSG00000182782 -1.63431 0.004407 0.343573 16.75071 7.19712 
IARS ENSG00000196305 -1.52221 0.004399 0.343573 179.65138 38.35739 
ASIC3 ENSG00000213199 -1.64902 0.004772 0.356253 5.23460 3.92570 
C10orf128 ENSG00000204161 -1.56316 0.004793 0.356253 106.15763 16.27531 
NPIPB3 ENSG00000169246 -1.19534 0.004767 0.356253 11.83019 12.75853 
PCSK6 ENSG00000140479 -1.54590 0.005122 0.37195 13.60995 4.17106 
HCAR3 ENSG00000255398 -1.38073 0.00543 0.38555 45.33161 18.64709 
ZNF365 ENSG00000138311 -1.49142 0.006091 0.42071 3.97829 4.57999 
SLC23A2 ENSG00000089057 -1.14633 0.006014 0.42071 92.65237 111.88253 
TEX10 ENSG00000136891 -1.12061 0.00609 0.42071 50.67090 20.69173 
ACTN2 ENSG00000077522 -2.66853 0.006336 0.429437 0.94223 0.16357 
SLC22A13 ENSG00000172940 -2.79511 0.00671 0.437588 1.46569 0.57250 
PI3 ENSG00000124102 -1.53938 0.006741 0.437588 13.08649 16.35710 
EPB41 ENSG00000159023 -0.99976 0.006723 0.437588 23.55569 23.22707 
39 
 
CDKN2A ENSG00000147889 -2.23960 0.007112 0.451928 1.67507 0.32714 
P2RX7 ENSG00000089041 -1.49521 0.007604 0.473355 210.43081 62.56589 
SCMH1 ENSG00000010803 -1.24468 0.007951 0.490561 17.69294 8.17855 
MPP6 ENSG00000105926 -1.51529 0.00817 0.501634 6.07213 2.94428 
TRMT6 ENSG00000089195 -1.46725 0.008368 0.511302 64.59493 12.43139 
SPRY1 ENSG00000164056 -3.06428 0.008687 0.515923 9.00351 0.24536 
TRIM25 ENSG00000121060 -0.92152 0.008849 0.52066 856.27544 701.22866 
IRS2 ENSG00000185950 -1.23255 0.009227 0.528084 218.91086 75.16085 
CAPN2 ENSG00000162909 -0.94622 0.009308 0.528084 186.14228 171.09521 
CCND2 ENSG00000118971 -2.17563 0.009728 0.53683 5.33929 0.65428 
TNFRSF10B ENSG00000120889 -1.10069 0.009757 0.53683 237.23195 109.59254 
SLC25A34 ENSG00000162461 -1.02595 0.009757 0.53683 30.57005 17.33852 
SYNJ2 ENSG00000078269 -1.68242 0.010528 0.564577 59.25564 12.92211 
PAX8 ENSG00000125618 -1.04596 0.010929 0.577977 17.48356 18.56530 
ARFGEF3 ENSG00000112379 -2.25655 0.01124 0.58338 0.73284 0.32714 
SLC4A5 ENSG00000188687 -1.37123 0.011659 0.60235 3.03607 3.10785 
KANK1 ENSG00000107104 -0.85305 0.01176 0.605081 51.50844 51.44306 
DUSP8 ENSG00000184545 -1.82339 0.011919 0.610806 7.22374 1.14500 
MELTF ENSG00000163975 -1.19988 0.012231 0.619322 10.46919 8.34212 
MYEOV ENSG00000172927 -2.66604 0.012808 0.627747 3.24545 0.08179 
MIA ENSG00000261857 -1.67167 0.012601 0.627747 2.19853 1.39035 
AARS ENSG00000090861 -1.22622 0.012722 0.627747 220.06247 76.79656 
FAM83G ENSG00000188522 -1.14003 0.012773 0.627747 33.92019 15.37567 
TCP11L2 ENSG00000166046 -0.99188 0.013051 0.627747 14.86626 13.98532 
AATK ENSG00000181409 -0.95344 0.012943 0.627747 18.11171 18.64709 
NPIPB4 ENSG00000185864 -0.85508 0.013083 0.627747 26.06829 26.00778 
ZCCHC14 ENSG00000140948 -0.84254 0.013069 0.627747 100.08550 67.30945 
JAG1 ENSG00000101384 -1.62305 0.013603 0.639408 67.10754 10.30497 
CHD7 ENSG00000171316 -1.01528 0.014712 0.672552 15.91318 14.96674 
KLF4 ENSG00000136826 -1.39181 0.014798 0.674072 13.60995 5.80677 
C5orf56 ENSG00000197536 -1.12691 0.015576 0.692168 10.57389 9.32354 
HMGA2 ENSG00000149948 -1.62042 0.015778 0.693261 16.96010 3.43499 
PRNP ENSG00000171867 -0.92703 0.015874 0.693261 151.59394 71.48051 
ID2 ENSG00000115738 -0.90394 0.015843 0.693261 107.83271 45.88165 
PPRC1 ENSG00000148840 -0.88673 0.015815 0.693261 78.10019 40.32024 
EPS8 ENSG00000151491 -1.72980 0.015981 0.695558 7.74720 1.22678 
MYBBP1A ENSG00000132382 -1.04551 0.0162 0.697809 29.31375 16.92959 
APOL6 ENSG00000221963 -0.94356 0.016332 0.698877 103.01688 76.14228 
CDRT1 ENSG00000241322 -2.25214 0.017072 0.711592 0.31408 0.89964 
NIPAL4 ENSG00000172548 -1.86420 0.017024 0.711592 15.80848 1.63571 
CRYM ENSG00000103316 -1.81166 0.017426 0.711592 1.04692 0.73607 
FNDC3A ENSG00000102531 -1.05784 0.017461 0.711592 281.62134 93.88973 
ITPR1 ENSG00000150995 -1.04614 0.017079 0.711592 226.02991 113.02753 
COA7 ENSG00000162377 -1.00895 0.017248 0.711592 26.17299 13.65817 
TTF2 ENSG00000116830 -0.91828 0.016941 0.711592 12.87711 14.96674 
HMGA1 ENSG00000137309 -0.87215 0.017469 0.711592 130.76024 104.68541 
ZC3H12C ENSG00000149289 -1.06638 0.0176 0.714631 241.00086 109.91968 
USP36 ENSG00000055483 -0.97006 0.018154 0.730049 110.45000 49.72557 
FBXO31 ENSG00000103264 -0.98591 0.018593 0.738441 17.48356 10.87747 
MFAP5 ENSG00000197614 -1.72401 0.019106 0.742926 2.93137 3.84392 
40 
 
CTRL ENSG00000141086 -1.14227 0.019174 0.742926 11.09735 6.13391 
CABLES1 ENSG00000134508 -1.82303 0.019551 0.746053 3.03607 0.65428 
RCL1 ENSG00000120158 -1.32000 0.019569 0.746053 4.18768 2.12642 
TSPOAP1 ENSG00000005379 -1.27663 0.019665 0.746053 5.44398 3.43499 
NFIX ENSG00000008441 -1.62458 0.020191 0.754711 0.83754 1.39035 
ATP2B1 ENSG00000070961 -1.26024 0.020184 0.754711 1141.24692 294.42771 
CHD9 ENSG00000177200 -0.81777 0.020107 0.754711 30.98882 25.84421 
EDN1 ENSG00000078401 -2.49085 0.020524 0.76092 62.29171 1.88107 
EIF5AL1 ENSG00000253626 -1.65323 0.020464 0.76092 1.25630 1.22678 
ARHGAP15 ENSG00000075884 -1.75588 0.021752 0.778354 27.21991 5.80677 
RP11-513I15.6 ENSG00000225339 -1.35054 0.021908 0.778354 3.24545 1.71749 
CAMKK2 ENSG00000110931 -0.66487 0.021984 0.778354 61.03541 66.73695 
GBP5 ENSG00000154451 -1.34588 0.022687 0.796478 14.23810 4.00749 
GNRH2 ENSG00000125787 -2.33070 0.023524 0.808567 0.52346 0.24536 
GPRC5A ENSG00000013588 -1.96645 0.023625 0.809295 0.62815 0.49071 
UBR4 ENSG00000127481 -0.86392 0.023833 0.81203 726.56212 534.14094 
ZFYVE9 ENSG00000157077 -1.36372 0.024203 0.818059 14.65687 3.59856 
ZNF117 ENSG00000152926 -0.77372 0.024087 0.818059 51.92721 35.41311 
P2RX4 ENSG00000135124 -0.92046 0.024334 0.818148 325.48727 134.37354 
IRF1 ENSG00000125347 -0.82999 0.02478 0.828762 167.92588 90.20938 
TNXB ENSG00000168477 -1.97756 0.025364 0.829555 0.52346 0.32714 
XYLB ENSG00000093217 -1.46349 0.025129 0.829555 1.67507 1.14500 
STEAP4 ENSG00000127954 -1.41706 0.025892 0.829555 10.99265 5.64320 
KCNA3 ENSG00000177272 -1.35309 0.0254 0.829555 1.88446 1.39035 
PMEPA1 ENSG00000124225 -1.29193 0.025592 0.829555 6.90967 3.27142 
NCR3LG1 ENSG00000188211 -0.99101 0.025812 0.829555 70.14360 32.71419 
DGKE ENSG00000153933 -0.79151 0.025291 0.829555 56.95242 39.01167 
PLA2G4A ENSG00000116711 -0.71224 0.025114 0.829555 76.73920 71.72586 
TNRC6C ENSG00000078687 -0.96586 0.02608 0.83233 17.69294 11.04104 
C19orf71 ENSG00000183397 -1.73225 0.026542 0.83251 2.72199 0.73607 
DRICH1 ENSG00000189269 -1.56242 0.02725 0.83251 0.94223 1.30857 
DGKD ENSG00000077044 -1.32844 0.026699 0.83251 175.46370 36.39454 
DDX43 ENSG00000080007 -1.18785 0.026812 0.83251 2.51261 2.78071 
MAML2 ENSG00000184384 -0.97855 0.027043 0.83251 142.59043 54.22377 
XPOT ENSG00000184575 -0.72991 0.026295 0.83251 102.70280 64.52874 
SH3D21 ENSG00000214193 -0.69455 0.026983 0.83251 65.74654 81.29476 
ZBTB11 ENSG00000066422 -0.74590 0.027447 0.836518 48.99583 31.48741 
F3 ENSG00000117525 -2.16053 0.028526 0.837945 1047.54763 44.65487 
GPD1 ENSG00000167588 -1.74336 0.027869 0.837945 1.15161 0.40893 
STOX2 ENSG00000173320 -1.57527 0.027977 0.837945 0.62815 7.27891 
CD22 ENSG00000012124 -1.27749 0.027787 0.837945 6.80498 5.23427 
JARID2 ENSG00000008083 -0.95966 0.029474 0.845571 582.50600 244.86571 
KLF10 ENSG00000155090 -0.78111 0.030058 0.851902 94.32744 72.21657 
TIPARP ENSG00000163659 -1.03045 0.030168 0.852008 348.20542 204.30012 
TMEM158 ENSG00000249992 -1.17883 0.030451 0.853832 15.70379 5.72498 
CCDC88B ENSG00000168071 -0.99362 0.030453 0.853832 37.27033 28.29777 
HIVEP2 ENSG00000010818 -0.81215 0.030736 0.856489 257.22812 176.57484 
RIMKLB ENSG00000166532 -0.76106 0.031108 0.859465 41.56270 29.03384 
RBM19 ENSG00000122965 -0.76382 0.031661 0.86721 91.71015 49.39843 
CDKN2B ENSG00000147883 -1.33418 0.03205 0.868998 140.60129 26.08957 
41 
 
LRP3 ENSG00000130881 -1.08697 0.032012 0.868998 4.18768 4.57999 
RBM28 ENSG00000106344 -0.71399 0.032308 0.87178 45.75038 33.61383 
AK4 ENSG00000162433 -0.72938 0.032897 0.880173 197.65840 178.37412 
FAM208B ENSG00000108021 -0.71693 0.033104 0.880306 81.03157 57.74055 
ABCE1 ENSG00000164163 -0.78373 0.033454 0.883933 48.36768 24.04493 
CYP1A1 ENSG00000140465 -1.97259 0.033695 0.886547 74.95943 10.87747 
FAM129A ENSG00000135842 -0.75713 0.033672 0.886547 378.14731 286.57630 
TAF4B ENSG00000141384 -1.32418 0.034131 0.890697 3.66422 2.20821 
SUMO4 ENSG00000177688 -2.03467 0.034295 0.892625 0.10469 0.57250 
MGEA5 ENSG00000198408 -0.75160 0.034345 0.892625 300.15181 210.84295 
AFAP1 ENSG00000196526 -1.48055 0.034517 0.893502 7.53782 5.64320 
BTN3A1 ENSG00000026950 -0.91212 0.03459 0.893502 29.41844 17.25674 
DBN1 ENSG00000113758 -1.24702 0.035003 0.895065 7.32844 3.59856 
NKX3-1 ENSG00000167034 -1.14152 0.034863 0.895065 34.44365 15.53924 
TRIM22 ENSG00000132274 -0.89535 0.034873 0.895065 26.69645 31.32384 
SLC9A8 ENSG00000197818 -0.67522 0.035204 0.896201 117.98782 96.99757 
COL1A2 ENSG00000164692 -2.13734 0.036415 0.897373 4.60645 0.40893 
DQX1 ENSG00000144045 -1.85822 0.037153 0.897373 0.83754 0.65428 
ADORA2B ENSG00000170425 -1.66084 0.035777 0.897373 2.30322 0.49071 
PTGER3 ENSG00000050628 -1.64948 0.03821 0.897373 0.94223 0.89964 
CUBN ENSG00000107611 -1.41988 0.036237 0.897373 3.35014 1.39035 
SPAG5-AS1 ENSG00000227543 -1.40625 0.035946 0.897373 12.14427 2.37178 
ANKRD33B ENSG00000164236 -1.31128 0.036936 0.897373 63.54801 13.16746 
CCDC88C ENSG00000015133 -1.30739 0.03733 0.897373 32.34981 6.95177 
CASP1 ENSG00000137752 -1.09221 0.037563 0.897373 729.49349 219.67579 
PHACTR1 ENSG00000112137 -1.00431 0.036127 0.897373 182.79214 79.49548 
AGAP6 ENSG00000204149 -0.78666 0.038377 0.897373 35.28119 20.11923 
KLHL21 ENSG00000162413 -0.77303 0.038028 0.897373 208.75574 134.45532 
HIVEP1 ENSG00000095951 -0.73266 0.036921 0.897373 147.19688 124.31392 




- 3 TSLPR+ 1 TSLPR+ 2 TSLPR+ 3 
SMAD3 6.82057 0.29515 1.18821 0.28575 
MYO10 50.53156 8.85463 24.03833 10.00125 
PPARG 20.75827 2.55800 3.01622 4.28625 
CARD16 79.77106 26.66228 29.24815 34.29001 
HS3ST2 5.21922 0.29515 0.27420 0.14288 
SNAPC1 105.27408 29.90898 26.32334 16.50207 
MMP10 308.58649 95.43325 79.24421 25.21744 
CDCP1 66.54508 18.00442 17.18329 16.85925 
IGFN1 43.11789 9.64171 25.22653 3.92906 
CCND1 8.30331 1.96770 1.37101 1.14300 
GPRC5C 12.09911 3.44347 2.46781 2.07169 
CCDC17 17.25902 6.09986 4.66142 3.85763 
ZEB1 3.38063 1.18062 0.45700 0.50006 
NDRG4 12.33634 0.39354 0.18280 0.64294 
OLIG2 51.24327 12.88841 5.57543 22.00276 
AEN 30.30707 17.31572 10.51105 5.64356 
RGS17 1.83859 0.09838 0.18280 0.07144 
SPINK1 88.07437 58.14542 26.14054 15.50194 
NCOR2 311.96712 136.16456 101.36313 97.36933 
CD244 3.38063 2.06608 0.73120 0.42863 
CD109 486.21796 98.58157 89.66387 84.22483 
DUSP16 30.12914 28.23644 14.34987 7.71525 
SH2D5 0.77102 0.19677 0.00000 0.00000 
PLPP3 53.43771 40.23938 15.17248 16.78782 
WHRN 11.09085 3.24670 3.56462 1.85738 
SYPL2 6.99850 0.59031 1.18821 0.85725 
AICDA 1.06757 0.00000 0.18280 0.00000 
TFPI2 152.84017 116.78275 19.10270 29.71801 
EML5 1.48273 0.09838 0.54840 0.07144 
TNFSF8 1.36411 0.98385 0.82260 0.21431 
KCNJ14 1.42342 0.29515 0.36560 0.28575 
HIVEP3 13.70046 8.55948 1.37101 2.57175 
ADAMTSL4-AS1 2.96547 1.67254 0.45700 0.28575 
DNHD1 46.73576 22.13658 22.02751 11.21569 
HCAR2 33.39116 5.90309 2.92482 9.50119 
IARS 95.72527 56.76803 29.06535 25.50319 
ASIC3 5.39715 2.26285 1.64521 0.71438 
C10orf128 82.79584 25.67843 15.17248 30.71813 
NPIPB3 21.76653 7.57563 6.39803 5.92931 
PCSK6 19.92794 3.24670 4.84423 5.07206 
HCAR3 75.02631 19.57857 9.23145 24.21732 
ZNF365 8.83709 1.37739 3.10762 1.71450 
SLC23A2 285.51516 74.37891 56.21129 84.65346 
TEX10 46.08336 21.05435 17.09189 16.50207 
ACTN2 2.60961 0.00000 0.27420 0.28575 
SLC22A13 0.59309 0.29515 0.00000 0.07144 
PI3 24.43545 1.08223 8.68305 9.14400 
EPB41 34.34011 13.87226 16.08648 10.35844 
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CDKN2A 1.66066 0.19677 0.36560 0.21431 
P2RX7 217.84320 100.35249 44.69483 26.28901 
SCMH1 13.16667 6.09986 5.94103 4.71488 
MPP6 4.98198 1.47577 2.46781 1.07156 
TRMT6 37.54281 20.36565 8.77445 13.14450 
SPRY1 1.42342 0.98385 0.27420 0.07144 
TRIM25 1099.47653 448.73306 557.08590 399.04997 
IRS2 104.85891 80.97069 51.91547 40.29076 
CAPN2 358.16910 101.82827 149.98818 118.65771 
CCND2 5.21922 1.08223 0.18280 1.21444 
TNFRSF10B 109.60366 79.79007 88.74986 50.86351 
SLC25A34 33.80632 13.97064 15.72088 10.78706 
SYNJ2 32.26428 20.66081 8.68305 3.28613 
PAX8 14.64941 8.06755 11.05946 5.50069 
ARFGEF3 1.77928 0.09838 0.18280 0.28575 
SLC4A5 3.55856 0.78708 1.91941 1.07156 
KANK1 83.38893 32.95891 44.87763 24.78882 
DUSP8 8.65916 1.86931 0.82260 2.14313 
MELTF 10.49775 2.95154 6.85504 3.21469 
MYEOV 1.54204 0.39354 0.09140 0.28575 
MIA 2.43168 0.88546 0.73120 0.28575 
AARS 113.57738 89.23501 54.01768 34.50432 
FAM83G 23.72374 15.44641 9.14005 8.71538 
TCP11L2 18.62313 7.08371 10.60246 6.28650 
AATK 26.33335 11.90456 8.40884 11.78719 
NPIPB4 32.14566 15.74157 17.54889 13.07307 
ZCCHC14 83.74479 56.57126 42.86682 40.71938 
JAG1 14.76803 16.03672 7.58624 7.64381 
CHD7 23.90166 8.65786 12.43046 6.00075 
KLF4 14.94595 6.98532 2.19361 3.71475 
C5orf56 18.44520 6.00147 7.76904 3.71475 
HMGA2 8.30331 4.52570 3.74742 1.35731 
PRNP 122.88895 75.75629 57.12530 50.57776 
ID2 83.50755 41.91192 37.93120 49.86339 
PPRC1 65.00304 40.23938 28.88255 30.71813 
EPS8 7.71021 2.36124 1.73661 1.00013 
MYBBP1A 23.72374 15.34803 7.86044 10.57275 
APOL6 158.77110 63.26142 79.06141 32.57551 
CDRT1 1.48273 0.39354 0.09140 0.07144 
NIPAL4 8.83709 3.73862 2.92482 0.78581 
CRYM 1.24550 0.09838 0.54840 0.21431 
FNDC3A 266.95134 128.49055 86.46485 96.51208 
ITPR1 267.12926 109.50228 133.71890 52.36370 
COA7 20.69896 12.19971 9.32285 8.78681 
TTF2 18.91968 8.26432 8.59164 7.64381 
HMGA1 218.43630 78.80622 65.53414 101.94134 
ZC3H12C 134.27634 113.14252 71.47517 48.86326 
USP36 79.71175 57.75188 31.25896 33.78995 
FBXO31 13.87839 6.49340 7.22064 7.92956 
MFAP5 21.35136 0.88546 3.19902 4.35769 
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CTRL 10.97223 4.82086 4.84423 3.21469 
CABLES1 1.36411 0.39354 0.63980 0.42863 
RCL1 4.27027 1.47577 1.27961 1.50019 
TSPOAP1 6.82057 2.75477 2.28501 1.42875 
NFIX 1.00826 0.19677 0.54840 0.28575 
ATP2B1 485.68418 414.59354 246.68989 159.80572 
CHD9 45.25303 18.20119 23.67272 16.07344 
EDN1 3.49925 8.95302 2.65061 1.07156 
EIF5AL1 2.66892 0.39354 0.18280 1.00013 
ARHGAP15 4.80406 6.88694 3.47322 1.21444 
RP11-513I15.6 5.45646 1.08223 1.37101 1.64306 
CAMKK2 67.73127 36.00884 44.60343 42.71963 
GBP5 11.74325 5.60793 4.11302 2.21456 
GNRH2 0.59309 0.00000 0.09140 0.14288 
GPRC5A 3.43994 0.49192 0.36560 0.28575 
UBR4 851.50418 440.46874 464.58862 252.10300 
ZFYVE9 13.52253 5.90309 4.20442 2.35744 
ZNF117 50.47225 26.85905 32.90417 21.64557 
P2RX4 220.57143 143.54342 110.50318 112.01403 
IRF1 136.23355 85.20123 69.55576 69.29439 
TNXB 1.54204 0.19677 0.18280 0.21431 
XYLB 1.77928 0.59031 0.73120 0.35719 
STEAP4 3.55856 3.83701 1.18821 2.57175 
KCNA3 2.66892 0.78708 0.82260 0.71438 
PMEPA1 9.72673 3.64024 2.74201 1.71450 
NCR3LG1 56.16594 40.23938 24.12973 15.35907 
DGKE 45.78681 32.27021 29.15675 20.78832 
PLA2G4A 66.01129 44.86347 53.56068 32.86126 
TNRC6C 11.86187 7.28047 7.95184 5.85788 
C19orf71 1.06757 0.39354 0.63980 0.35719 
DRICH1 1.42342 0.39354 0.63980 0.21431 
DGKD 44.77855 57.25995 28.33415 20.00250 
DDX43 4.56682 1.37739 1.64521 1.28588 
MAML2 81.13518 65.32751 48.07665 29.93232 
XPOT 101.24104 54.80033 58.67911 49.93482 
SH3D21 79.83037 43.19093 62.15232 34.29001 
ZBTB11 46.32059 23.71074 29.06535 23.86013 
F3 121.22829 215.26594 43.41523 21.50269 
GPD1 1.30481 0.29515 0.18280 0.35719 
STOX2 5.51577 1.08223 2.10221 1.14300 
CD22 3.38063 2.85316 1.09681 2.35744 
JARID2 537.10538 327.32622 182.16115 190.80961 
KLF10 130.77709 71.23059 60.78132 38.79057 
TIPARP 519.37188 271.34527 92.22308 145.08960 
TMEM158 14.29355 3.04993 4.02162 9.21544 
CCDC88B 20.63965 19.38181 17.27469 6.71513 
HIVEP2 231.18780 152.59482 143.31595 83.08183 
RIMKLB 42.10963 23.21881 27.14594 16.57350 
RBM19 68.85814 48.60209 38.29680 38.00476 
CDKN2B 49.40468 51.55363 23.30712 12.71588 
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LRP3 3.20270 1.67254 2.01081 1.92881 
RBM28 51.36189 27.94128 28.15135 23.71726 
AK4 186.40925 111.96190 144.96116 83.86764 
FAM208B 88.01506 53.22618 49.17346 35.29013 
ABCE1 46.32059 23.12043 21.93611 24.86026 
CYP1A1 40.74552 27.64613 1.18821 2.42888 
FAM129A 575.65645 218.51263 278.49725 238.45843 
TAF4B 2.37237 1.67254 0.82260 0.78581 
SUMO4 1.12688 0.09838 0.18280 0.14288 
MGEA5 423.82454 171.18955 201.35525 184.52310 
AFAP1 2.19445 2.85316 2.10221 0.57150 
BTN3A1 25.62163 15.44641 15.81228 7.42950 
DBN1 5.51577 3.54185 2.10221 1.28588 
NKX3-1 12.92944 14.06903 10.51105 4.42913 
TRIM22 26.45197 12.69164 25.50073 7.57238 
SLC9A8 137.83490 77.33045 76.04520 67.07983 
COL1A2 1.77928 0.98385 0.00000 0.57150 
DQX1 0.41517 0.00000 0.27420 0.21431 
ADORA2B 1.60135 0.68869 0.27420 0.42863 
PTGER3 0.65240 0.09838 0.54840 0.14288 
CUBN 7.88814 2.16447 1.18821 1.28588 
SPAG5-AS1 4.21096 3.24670 2.37641 1.71450 
ANKRD33B 17.49626 22.53012 8.31744 8.07244 
CCDC88C 12.98875 12.29810 5.20983 4.00050 
CASP1 298.14805 308.23957 164.61226 123.37259 
PHACTR1 103.96927 97.59772 53.65208 31.57538 
AGAP6 34.34011 19.77534 14.71548 17.71650 
KLHL21 175.14048 126.91639 101.82013 74.72364 
HIVEP1 126.86268 88.44793 96.33610 55.36408 
POFUT2 67.96850 52.04556 42.13562 33.93282 
 




 Supplementary Table II 
Upregulated gene transcripts in TSLPR+ vs TSLPR- 
Gene_Symbol Ensembl_ID logFC       PValue                       FDR               TSLPR- 1 TSLPR- 2 
CCR7 ENSG000001 5.92136 8.48E-33 1.08E-28 2.09384 0.98143 
CRLF2 ENSG000002 4.31192 1.22E-15 7.73E-12 0.62815 2.69892 
LAMP3 ENSG000000 2.92873 9.05E-14 3.84E-10 5.12991 8.34212 
MMP12 ENSG000002 5.05779 2.99E-09 9.48E-06 0.10469 0.00000 
LAD1 ENSG000001 2.92657 5.50E-09 1.40E-05 2.30322 3.68035 
MMP7 ENSG000001 3.57325 1.07E-07 0.00022674 0.00000 0.65428 
SORBS3 ENSG000001 1.93634 2.30E-07 0.000417 5.65337 9.15997 
HLA-DPA1 ENSG000002 3.20816 7.36E-07 0.00116933 1.46569 4.49820 
TNNT2 ENSG000001 4.72354 1.55E-06 0.0021818 0.00000 0.32714 
CD1C ENSG000001 2.90283 2.06E-06 0.00262088 0.52346 0.98143 
C1QC ENSG000001 4.42795 3.81E-06 0.00372442 0.00000 0.08179 
CD86 ENSG000001 2.31629 3.71E-06 0.00372442 6.70028 5.39784 
FCRLB ENSG000001 1.81799 3.29E-06 0.00372442                6.07213 9.89604 
GCSAM ENSG000001 7.38957 4.38E-06 0.00397431 0.00000 0.00000 
HLA-DMA ENSG000002 2.23696 4.87E-06 0.00412571 2.51261 6.54284 
CD1E ENSG000001 4.63580 5.24E-06 0.00416554 0.00000 0.08179 
NCCRP1 ENSG000001 3.37687 5.73E-06 0.00428214 0.31408 0.57250 
PALLD ENSG000001 2.79352 6.08E-06 0.00429124 1.88446 0.98143 
MRC1 ENSG000002 2.14711 6.86E-06 0.00453111 55.69612 61.58446 
FCGR2B ENSG000000 1.90329 7.13E-06 0.00453111 28.99967 53.48770 
FBN1 ENSG000001 4.86998 9.44E-06 0.00571561                 0.00000 0.00000 
CD74 ENSG000000 2.21217 1.02E-05 0.00589131 25.23076 57.90412 
HLA-DPB1 ENSG000002 3.44168 1.95E-05 0.00991161 0.20938 2.12642 
TFRC ENSG000000 1.44415 1.94E-05 0.00991161 89.93038 149.99456 
SLC22A23 ENSG000001 3.19985 2.25E-05 0.01100605 0.52346 0.32714 
EMP2 ENSG000002 3.00482 2.41E-05 0.01135161 0.41877 0.24536 
CXCL13 ENSG000001 4.83078 2.75E-05 0.01248542 0.00000 0.24536 
CALCRL ENSG000000 3.45618 3.13E-05 0.01325742 0.10469 0.00000 
TSPAN15 ENSG000000 6.32592 3.48E-05 0.01383548 0.00000 0.00000 
CST7 ENSG000000 4.47423 3.77E-05 0.01452565 0.00000 0.16357 
GAS6 ENSG000001 2.18668 4.21E-05 0.01574797 0.73284 1.22678 
C1QB ENSG000001 4.71325 8.44E-05 0.02820578 0.00000 0.00000 
CLEC4F ENSG000001 3.54810 8.66E-05 0.02820578 0.00000 0.16357 
HLA-DMB ENSG000002 2.52745 8.16E-05 0.02820578 0.73284 4.00749 
MGAT4A ENSG000000 1.51420 8.49E-05 0.02820578 10.88796 36.39454 
CYP2S1 ENSG000001 1.48732 7.80E-05 0.02820578 6.90967 18.48352 
NAV2 ENSG000001 1.70002 9.38E-05 0.02978677 3.03607 8.09676 
HLA-DRA ENSG000002 2.10949 9.85E-05 0.03053022 17.27417 45.96344 
ZNF366 ENSG000001 3.38549 0.0001202
5 
0.03568927 0.00000 0.08179 
CYP27B1 ENSG000001 2.29316 0.0001207
5 
0.03568927 2.61730 17.82923 
ROBO1 ENSG000001 3.06709 0.0001240
2 
0.03582306                0.0000 0.40893 
MT1E ENSG000001 1.51442 0.0001303
2 



























0.04561564 1.04692 1.22678 
HLA-DRB1 ENSG000001 2.0232
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0.04704797 2.09384 4.66177 
RTN1 ENSG000001 1.9404
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0.05819395 1.57038 2.53535 
ITIH1 ENSG000000 1.7273
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0.07206409 9.94574 29.85170 
FPR2 ENSG000001 1.3926
5 
0.0004334 0.07982752 20.20555 28.87027 
HLA-DOA ENSG000002 3.4820
8 















0.09377479 4.08299 13.65817 
TNFRSF6B ENSG000002 1.7890
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0.13580588 18.53047 59.37625 
CCL24 ENSG000001 2.8445
5 






























0.17430946 0.94223 1.79928 
SLC1A2 ENSG000001 1.9358
9 
0.0014766 0.17430946 0.62815 3.18963 
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ADAMTS14 ENSG000001 1.15404 0.00148127 0.17430946 30.15128 92.49937 
FLT3 ENSG000001 2.93720 0.0017672 0.19529911 0.00000 0.00000 
PPBP ENSG000001 1.81279 0.00213493 0.22686723 2.61730 14.47603 
CLIC2 ENSG000001 1.32997 0.00214211 0.22686723 5.23460 4.00749 
PECAM1 ENSG000002 1.74072 0.00218924 0.22805741 1.46569 10.87747 
CD207 ENSG000001 3.14747 0.00222798 0.23020697 0.00000 0.00000 
CLEC6A ENSG000002 2.77355 0.00224626 0.23022374 0.00000 1.06321 
RARRES1 ENSG000001 4.21766 0.00237821 0.23798973 0.00000 0.08179 
TIAM1 ENSG000001 1.07797 0.00234485 0.23798973 12.77242 23.39065 
CLEC10A ENSG000001 3.06278 0.00240479 0.23876914 0.00000 1.71749 
A2M ENSG000001 2.34654 0.00249002 0.24342825 7.64251 0.98143 
TMEM173 ENSG000001 1.40243 0.00252957 0.2454066 3.14076 12.67675 
FPR1 ENSG000001 1.60648 0.00260164 0.24860323 17.79763 28.95206 
CYGB ENSG000001 2.65923 0.00272464 0.25841357 0.10469 0.16357 
ITGA4 ENSG000001 1.43868 0.00284705 0.26605279 1.77976 3.51678 
CCR6 ENSG000001 2.63174 0.00295308 0.271962 0.00000 0.16357 
ADCY6 ENSG000001 1.94074 0.00301071 0.27527437 0.20938 0.65428 
PTPRF ENSG000001 2.25034 0.00324146 0.28474982 0.20938 1.88107 
GSN ENSG000001 1.58351 0.00322994 0.28474982 33.18735 85.30225 
ZNF395 ENSG000001 1.23883 0.0033302 0.28474982 9.84104 21.10065 
ACTG1 ENSG000001 1.13673 0.00321323 0.28474982 228.75191 266.45708 
STEAP3 ENSG000001 1.07952 0.00337314 0.28579533 22.09000 53.65127 
TIFAB ENSG000002 2.48691 0.00351235 0.29561865 0.00000 1.39035 
FAM124A ENSG000001 1.10765 0.00360654 0.30154922 6.70028 10.87747 
LMO2 ENSG000001 1.15810 0.00367568 0.30532145 8.37536 12.10425 
NDRG2 ENSG000001 2.75010 0.00383021 0.30808952 0.10469 0.98143 
TNFAIP8L2 ENSG000001 1.05979 0.00381707 0.30808952 9.94574 24.04493 
CP ENSG000000 3.20056 0.00386065 0.30858521 0.00000 0.16357 
HNMT ENSG000001 1.22254 0.00400587 0.31819163 18.73986 65.67374 
UGCG ENSG000001 0.83322 0.00411217 0.3246062 37.47972 51.52485 
TREM2 ENSG000000 3.57751 0.00464316 0.35625298 0.10469 0.16357 
INSM1 ENSG000001 2.61161 0.0046601 0.35625298 0.00000 0.24536 
C1orf54 ENSG000001 2.15448 0.00471532 0.35625298 0.31408 0.65428 
FABP5 ENSG000001 1.63150 0.0047066 0.35625298 2.19853 2.53535 
TNFSF13 ENSG000001 1.52666 0.00477398 0.35625298 8.79412 9.32354 
KCP ENSG000001 1.83386 0.00497715 0.36563332 0.83754 1.55392 
ALDH2 ENSG000001 1.72255 0.00494882 0.36563332 1.88446 9.56890 
SPRED1 ENSG000001 0.93333 0.00502824 0.36726414 24.70730 37.37596 
MROH7 ENSG000001 2.49341 0.00541536 0.38555004 0.00000 0.08179 
PPP1R14C ENSG000001 2.35638 0.00542516 0.38555004 0.00000 0.16357 
RAB3D ENSG000001 1.14058 0.00558806 0.39454773 7.01436 25.35350 
PLEKHG1 ENSG000001 3.35173 0.00608843 0.42071014 0.00000 0.00000 
ZG16B ENSG000001 2.23748 0.00613416 0.42140012 0.10469 0.16357 
FGL2 ENSG000001 1.93865 0.00635251 0.42943661 0.62815 1.88107 
49 
 
LY86 ENSG000001 1.57261 0.00630677  0.42943661 1.25630 1.30857 
C1QA ENSG000001 3.12957 0.00676127 0.43758812 0.10469 0.00000 
BCL7A ENSG000001 1.52727 0.00678254 0.43758812 0.94223 1.88107 
FADS2 ENSG000001 1.35624 0.00660807 0.43758812 2.09384 7.27891 
SIGLEC7 ENSG000001 1.25948 0.00661329 0.43758812 21.04308 29.52456 
CD4 ENSG000000 1.81952 0.00699447 0.44717453 0.83754 7.52426 
LDHA ENSG000001 1.11865 0.00700195 0.44717453 107.30925 284.61345 
GCAT ENSG000001 2.10959 0.00763536 0.47335478 0.20938 0.24536 
CD1D ENSG000001 2.00980 0.00750392 0.47335478 0.73284 0.32714 
FAM20C ENSG000001 0.98722 0.00762178 0.47335478 33.18735 81.29476 
LYZ ENSG000000 1.72195 0.00849599 0.51184409 105.11072 1590.07321 
LXN ENSG000000 1.56982 0.00849784 0.51184409 1.36100 4.00749 
CECR6 ENSG000001 1.14609 0.00843605 0.51184409 4.92052 13.73996 
NCEH1 ENSG000001 0.86580 0.00867547 0.51592288 17.06479 32.87776 
H2AFY2 ENSG000000 2.38014 0.00877476 0.51869013 0.00000 0.65428 
DLL4 ENSG000001 2.37037 0.00896774 0.52382676 0.00000 0.40893 
CD36 ENSG000001 1.51881 0.00898823 0.52382676 1.88446 15.37567 
PROCR ENSG000001 0.89521 0.00902652 0.52382676 14.13341 21.26422 
PSD3 ENSG000001 1.28883 0.00913736 0.52593734 4.71114 3.27142 
MMP9 ENSG000001 1.15941 0.00914566 0.52593734 3941.33775 2495.35663 
LGALS1 ENSG000001 0.87579 0.00928052 0.5280845 112.02038 206.83547 
SMTNL2 ENSG000001 3.11497 0.00953704 0.53660666 0.00000 0.16357 
OTUD7B ENSG000002 1.34009 0.00971315 0.53682952 1.25630 2.94428 
ACTB ENSG000000 1.00141 0.00966644 0.53682952 768.43890 1688.95185 
CD209 ENSG000000 0.94700 0.00980846 0.53730906 12.14427 28.54313 
HSPB1 ENSG000001 1.22354 0.00996265 0.54341326 4.39706 18.56530 
ARHGDIB ENSG000001 1.17305 0.01014026 0.5507376 59.46503 215.50473 
FSCN1 ENSG000000 0.96051 0.01029482 0.55675237 9.84104 10.55033 
SYT1 ENSG000000 3.02027 0.0103769 0.55881359 0.00000 0.00000 
IGFBP7 ENSG000001 1.33779 0.01071294 0.5720622 0.94223 2.94428 
C6orf223 ENSG000001 1.36043 0.01093324 0.5779775 0.94223 1.63571 
CTSB ENSG000001 0.94605 0.01096015 0.5779775 1410.93338 3474.90126 
RAMP1 ENSG000001 2.71212 0.011009 0.57815473 0.31408 0.00000 
FRMD4A ENSG000001 1.73066 0.01112211 0.58169078 0.31408 2.28999 
ADGRE3 ENSG000001 1.18132 0.01124621 0.5833799 33.81550 50.29807 
ITIH3 ENSG000001 1.83943 0.01203823 0.61197532 0.20938 0.49071 
ASGR2 ENSG000001 2.64327 0.01246568 0.62372584 0.00000 0.32714 
ZCWPW2 ENSG000002 2.26690 0.01241915 0.62372584 0.00000 0.00000 
PROS1 ENSG000001 1.66427 0.01311228 0.62774674 0.10469 1.47214 
CLDN23 ENSG000002 1.22522 0.01313877 0.62774674 5.75806 9.81426 
LMNB1 ENSG000001 1.14826 0.01279842 0.62774674 2.82668 8.75105 
TPI1 ENSG000001 0.84497 0.01303232 0.62774674 137.14645 244.86571 
HVCN1 ENSG000001 1.35639 0.01322709 0.62959973 2.19853 9.73247 
CD300LF ENSG000001 1.17151 0.01333462 0.62999904 6.90967 25.84421 
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RCAN ENSG000001 0.83268 0.0136344 0.63940792 10.88796 20.36458 
WNT5A ENSG000001 0.94188 0.01382574 0.64599737 25.64953 56.67733 
SCD5 ENSG000001 2.30274 0.01394556 0.64920927 0.00000 0.16357 
CLEC4G ENSG000001 1.96864 0.0143069 0.66359974 0.10469 0.24536 
CACNA2D3 ENSG000001 2.52225 0.01458153 0.67143723 0.62815 0.08179 
EMILIN1 ENSG000001 1.19232 0.0145656 0.67143723 15.70379 93.48080 
DTNA ENSG000001 1.49820 0.01465858 0.67254848 0.41877 2.12642 
IL4I1 ENSG000001 0.82035 0.01499244 0.68049626 78.41427 132.65604 
SLA ENSG000001 1.61453 0.01507016 0.68158956 10.15512 42.85559 
AUTS2 ENSG000001 1.96100 0.01518002 0.68231083 0.20938 0.08179 
CCND3 ENSG000001 1.18190 0.01519348 0.68231083 25.12607 133.47390 
SLAMF1 ENSG000001 1.17236 0.01525578 0.68269603 63.33863 48.74414 
NLRC5 ENSG000001 0.84648 0.0154075 0.68706621 15.28502 30.17884 
ACOT11 ENSG000001 1.53742 0.01583701 0.69326097 1.04692 1.14500 
PTPRO ENSG000001 1.82226 0.01607471 0.69724739 0.62815 4.49820 
TTYH2 ENSG000001 1.32919 0.01615917 0.69780891 2.40791 4.08927 
STAT4 ENSG000001 1.08457 0.01625238 0.69780891 3.14076 4.98891 
TNNT1 ENSG000001 2.18702 0.01683454 0.71159226 0.00000 0.49071 
LDHB ENSG000001 1.18454 0.01745499 0.71159226 2.30322 5.39784 
IDO1 ENSG000001 1.05374 0.01694049 0.71159226 49.51929 188.35195 
FAM200B ENSG000002 0.85526 0.0172589 0.71159226 10.88796 14.55781 
TAX1BP3 ENSG000002 0.82901 0.01675199 0.71159226 26.06829 58.06769 
CERS6 ENSG000001 0.76350 0.01779676 0.72031547 21.04308 38.52096 
FCGRT ENSG000001 0.99039 0.01799161 0.7258899 61.66356 214.11437 
TRAF5 ENSG000000 1.59092 0.01820957 0.73004874 1.25630 0.57250 
IVD ENSG000001 1.17211 0.01843461 0.7367468 2.09384 3.76213 
COLEC12 ENSG000001 2.35582 0.01851445 0.73761797 0.31408 0.49071 
LGALS2 ENSG000001 3.27418 0.01873096 0.73883498 0.10469 0.16357 
DNAJC5B ENSG000001 1.20349 0.01867298 0.73883498 1.36100 5.31606 
SPARC ENSG000001 1.19846 0.01877754 0.73883498 3.35014 3.92570 
ZC4H2 ENSG000001 1.76372 0.01917057 0.74292562 0.20938 0.40893 
VSIG4 ENSG000001 1.66126 0.01899894 0.74292562 0.20938 0.65428 
AIF1 ENSG000002 1.12556 0.01900045 0.74292562 9.84104 39.42060 
RPGRIP1 ENSG000000 2.99181 0.01963206 0.74605297 0.00000 0.32714 
BUB1 ENSG000001 2.04761 0.01937284 0.74605297 0.00000 0.24536 
MT1G ENSG000001 1.44919 0.01949291 0.74605297 4.60645 22.08208 
CLU ENSG000001 1.81307 0.0200935 0.75471126 0.00000 1.63571 
LINC01420 ENSG000002 1.10343 0.01996524 0.75471126 5.54867 4.82534 
JAML ENSG000001 2.50955 0.02053628 0.7609202 0.00000 6.95177 
PKIB ENSG000001 2.63401 0.02095124 0.76734671 0.00000 0.08179 
PTRF ENSG000001 1.92579 0.02085766 0.76734671 0.10469 0.24536 
MT-ND6 ENSG000001 0.84084 0.02091935 0.76734671 27.32460 31.07848 
FAT2 ENSG000000 2.99969 0.02119108 0.76994993 0.00000 0.08179 
CRIP1 ENSG000002 1.34436 0.02120407 0.76994993 0.94223 1.47214 
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GLRX ENSG000001 1.02232 0.02109464 0.76994993 38.73602 182.46339 
TBX3 ENSG000001 2.70690 0.02131041 0.77160672 0.00000 0.16357 
AP2S1 ENSG000000 0.71289 0.02138486 0.77210276 30.25597 57.24983 
HLA-DQA2 ENSG000002 2.04901 0.02174999 0.77835372 3.76891 0.57250 
FZD3 ENSG000001 1.53488 0.02186012 0.77835372 0.20938 0.65428 
AK8 ENSG000001 1.50033 0.02184895 0.77835372 0.83754 1.55392 
TBC1D4 ENSG000001 1.38835 0.0219867 0.77835372 1.15161 1.96285 
GUCY1B3 ENSG000000 1.81479 0.02231781 0.78788066 0.10469 0.24536 
C16orf45 ENSG000001 1.89354 0.02238224 0.78796648 0.41877 0.32714 
ABCG1 ENSG000001 1.14178 0.02281773 0.79887203 1.46569 3.92570 
GP1BA ENSG000001 2.02337 0.02292378 0.80037996 0.10469 0.32714 
BICC1 ENSG000001 2.04728 0.02316142 0.80425813 0.31408 0.08179 
FAIM ENSG000001 1.16326 0.02314381 0.80425813 1.25630 4.08927 
CYFIP2 ENSG000000 1.11346 0.02325513 0.80531171 4.71114 3.10785 
PROB1 ENSG000002 1.47300 0.02354 0.80856719 0.31408 0.73607 
IGFLR1 ENSG000001 0.91927 0.02348949 0.80856719 18.73986 61.74803 
FBXO6 ENSG000001 0.86865 0.02378223 0.81203029 6.70028 13.24925 
SLCO2B1 ENSG000001 2.25573 0.02416183 0.81805855 0.00000 7.76962 
RFTN1 ENSG000001 0.83614 0.024286 0.81814808 66.58408 181.15483 
C10orf10 ENSG000001 2.45471 0.02451167 0.82194939 0.00000 0.16357 
SLAMF9 ENSG000001 1.86200 0.02545618 0.82955512 0.31408 0.32714 
S100A9 ENSG000001 1.22198 0.02488856 0.82955512 177.03408 1361.56459 
CHI3L2 ENSG000000 1.21006 0.02586814 0.82955512 1.88446 7.03355 
SPATS2 ENSG000001 1.14865 0.0259134 0.82955512 1.67507 5.56141 
ALDOC ENSG000001 1.07549 0.0257545 0.82955512 5.86275 7.11534 
UCP2 ENSG000001 1.01340 0.02533942 0.82955512 46.27384 169.78665 
DENND3 ENSG000001 0.81870 0.02570813 0.82955512 53.70697 69.51765 
PLEKHG2 ENSG000000 0.80689 0.02542946 0.82955512 54.54450 74.58835 
GPI ENSG000001 0.76580 0.02579587 0.82955512 22.71815 56.35019 
PSRC1 ENSG000001 1.99632 0.02668427 0.83250993 0.00000 0.24536 
PLCL1 ENSG000001 1.46557 0.02724161 0.83250993 0.41877 3.43499 
SPECC1 ENSG000001 1.07287 0.02724728 0.83250993 2.51261 3.68035 
DBNDD2 ENSG000002 0.86537 0.02709725 0.83250993 8.06128 17.25674 
PLXNC1 ENSG000001 0.84129 0.0269111 0.83250993 57.68526 139.52602 
P4HA1 ENSG000001 0.76306 0.0271877 0.83250993 49.72868 87.51046 
LAP3 ENSG000000 0.68831 0.02687039 0.83250993 21.77593 27.47992 
IL21R ENSG000001 2.02014 0.02852421 0.83794522 0.00000 0.89964 
NDP ENSG000001 1.90121 0.02786855 0.83794522 0.00000 2.20821 
FZD2 ENSG000001 1.77635 0.02758941 0.83794522 0.31408 1.14500 
CARD9 ENSG000001 1.23639 0.02798654 0.83794522 2.09384 7.44248 
ATF7IP2 ENSG000001 1.16292 0.02836448 0.83794522 1.25630 4.00749 
METTL1 ENSG000000 1.12986 0.02812534 0.83794522 2.09384 4.82534 
LRP5 ENSG000001 1.12867 0.02843622 0.83794522 4.18768 2.45356 
ANXA6 ENSG000001 1.06919 0.02860237 0.83794522 6.07213 27.47992 
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MT2A ENSG000001 0.97943 0.02852209 0.83794522 193.05195 112.53681 
CPM ENSG000001 0.79663 0.02840884 0.83794522 45.64569 46.12701 
C3orf14 ENSG000001 1.22939 0.02874625 0.839853 1.57038 2.86249 
DOCK1 ENSG000001 0.94715 0.02887488 0.84167633 5.12991 17.42031 
VASH1 ENSG000000 1.37715 0.02904584 0.84279352 2.93137 42.93737 
PLBD1 ENSG000001 1.33786 0.02904437 0.84279352 2.09384 16.35710 
KCTD12 ENSG000001 0.89309 0.02913993 0.84359774 36.32811 129.13927 
ZHX3 ENSG000001 1.18857 0.02946888 0.84557115 1.15161 1.47214 
TRPM4 ENSG000001 1.11228 0.02938135 0.84557115 2.40791 8.26033 
H1F0 ENSG000001 0.87494 0.02941129 0.84557115 82.28787 212.56045 
PLEKHO1 ENSG000000 0.78469 0.02961752 0.84776828 86.37086 220.00293 
FPR3 ENSG000001 1.80791 0.02980912 0.84871705 3.97829 42.61023 
ID3 ENSG000001 1.75670 0.03009711 0.8519023 0.20938 4.08927 
KIAA1211L ENSG000001 1.61605 0.03056839 0.85383212 0.10469 0.24536 
SAMHD1 ENSG000001 1.06994 0.0305401 0.85383212 24.70730 113.51824 
SPINT2 ENSG000001 0.73814 0.03040711 0.85383212 24.81199 27.23456 
VMO1 ENSG000001 1.29596 0.0308848 0.85701941 0.94223 3.59856 
FAM101B ENSG000001 0.90776 0.03099482 0.85819855 15.38972 25.84421 
CIITA ENSG000001 1.33362 0.03158398 0.86695648 3.55953 39.33881 
TMEM176A ENSG000000 1.01810 0.03153408 0.86695648 11.51611 47.51736 
MRC2 ENSG000000 1.49193 0.03183242 0.86899786 1.77976 0.89964 
ZNF680 ENSG000001 1.49188 0.03206861 0.86899786 0.52346 0.81785 
TNFRSF4 ENSG000001 0.95182 0.03199163 0.86899786 6.17682 6.29748 
ZFP36L1 ENSG000001 0.79215 0.03214768 0.86928706 74.54067 183.93553 
PRR11 ENSG000000 1.68672 0.03237783 0.87180057 0.20938 1.14500 
C2orf74 ENSG000002 1.19690 0.03274756 0.87923147 1.25630 2.04464 
NDN ENSG000001 2.31484 0.03310932 0.88030621 0.10469 0.00000 
CENPE ENSG000001 1.48589 0.03305497 0.88030621 0.20938 1.79928 
MCM6 ENSG000000 1.07850 0.03322346 0.88056582 2.40791 4.41642 
VGLL4 ENSG000001 0.99922 0.03325766 0.88056582 11.62081 16.27531 
IL16 ENSG000001 0.75665 0.0337626 0.88654723 45.95977 65.10124 
TPCN1 ENSG000001 0.78615 0.0338552 0.88714594 14.02872 31.16027 
GSPT2 ENSG000001 1.13206 0.0339335 0.88736789 1.04692 1.63571 
RGS14 ENSG000001 0.87135 0.0345401 0.89350204 5.86275 13.41282 
CXCR5 ENSG000001 1.73918 0.03476198 0.89506487 1.04692 1.30857 
CKB ENSG000001 0.90785 0.03499372 0.89506487 5.23460 6.21570 
NR1H3 ENSG000000 1.39820 0.03519043 0.89620143 1.57038 3.68035 
SLC44A2 ENSG000001 0.96540 0.03532905 0.89620143 5.44398 17.33852 
GIPC3 ENSG000001 1.88330 0.03693654 0.89737299 0.00000 0.24536 
HAPLN3 ENSG000001 1.63442 0.03613056 0.89737299 0.41877 0.32714 
SMYD3 ENSG000001 1.53590 0.03778742 0.89737299 0.31408 0.32714 
THBS2 ENSG000001 1.51068 0.03587375 0.89737299 0.41877 2.69892 
MMP2 ENSG000000 1.44224 0.03728665 0.89737299 0.62815 0.73607 
STMN1 ENSG000001 1.35416 0.0365167 0.89737299 0.52346 0.98143 
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YPEL4 ENSG000001 1.33911 0.03698169 0.89737299 2.61730 1.96285 
CAMK1 ENSG000001 1.25989 0.03655905 0.89737299 1.88446 8.26033 
CATIP-AS1 ENSG000002 1.25395 0.03822447 0.89737299 1.04692 0.81785 
RNASE6 ENSG000001 1.19792 0.03794011 0.89737299 2.61730 3.27142 
DDX11 ENSG000000 1.14820 0.03721663 0.89737299 4.71114 4.74356 
LOXL2 ENSG000001 1.13386 0.03706242 0.89737299 1.36100 2.69892 
SLC16A10 ENSG000001 1.07435 0.0359224 0.89737299 27.21991 18.89244 
METTL21B ENSG000001 1.04279 0.03670344 0.89737299 2.82668 10.71390 
ZNF469 ENSG000002 1.00749 0.0371747 0.89737299 3.66422 6.37927 
ST6GAL1 ENSG000000 0.95466 0.03841637 0.89737299 3.14076 4.41642 
VAMP8 ENSG000001 0.89987 0.03757568 0.89737299 11.51611 29.52456 
KCNE3 ENSG000001 0.86212 0.03797963 0.89737299 9.73635 35.57668 
ARL3 ENSG000001 0.83677 0.038623 0.89737299 6.17682 13.08568 
DRAM2 ENSG000001 0.76361 0.03681027 0.89737299 18.00701 43.75523 
SLC11A1 ENSG000000 0.70081 0.03678966 0.89737299 478.96566 723.80145 





- 3 TSLPR+ 1 TSLPR+ 2 TSLPR+ 3 
CCR7 0.77102 73.19829 56.11989        99.51246     
99.51246 CRLF2 0.71171 23.71074 31.99017 22.78857 
LAMP3 9.25226 31.18798 63.15773 79.79571 
MMP12 0.11862 3.34508 2.10221 3.00038 
LAD1 2.49099 8.55948 29.43095 27.57488 
MMP7 0.53378 3.34508 4.47862 7.00088 
SORBS3 7.29505 29.12190 24.58673 29.36082 
HLA-DPA1 5.75301 12.79002 17.18329 78.00977 
TNNT2 0.11862 0.49192 5.39263 7.07231 
CD1C 0.77102 5.21439 3.10762 8.64394 
C1QC 0.05931 1.77093 0.63980 1.35731 
CD86 18.74175 41.81354 29.33955 81.22446 
FCRLB 7.35436 29.31867 31.99017 19.50244 
GCSAM 0.00000 0.29515 0.73120 4.07194 
HLA-DMA 7.05781 17.02057 15.90368 41.93382 
CD1E 0.17793 1.18062 0.82260 5.85788 
NCCRP1 0.05931 3.24670 1.91941 4.28625 
PALLD 1.18619 4.32893 7.86044 16.71638 
MRC1 90.62467 286.89007 113.88499 506.49199 
FCGR2B 92.10740 215.26594 137.74052 278.24913 
FBN1 0.17793 0.29515 2.01081 4.85775 
CD74 22.83410 85.98831 93.13709 308.89582 
HLA-DPB1 2.01652 4.72247 6.30663 36.14738 
TFRC 101.71552 259.73586 383.51640 278.74919 
SLC22A23 0.53378 0.98385 5.20983 7.14375 
EMP2 0.23724 3.04993 2.37641 1.71450 
CXCL13 0.11862 0.09838 3.47322 8.07244 
CALCRL 0.23724 0.78708 1.73661 1.85738 
TSPAN15 0.00000 0.19677 1.46241 0.78581 
CST7 0.05931 0.29515 1.00541 4.42913 
GAS6 1.18619 3.83701 4.11302 6.42938 
C1QB 0.05931 1.27900 0.36560 1.00013 
CLEC4F 0.29655 0.98385 0.82260 4.28625 
HLA-DMB 2.78754 10.62556 5.48403 26.07469 
MGAT4A 31.31533 51.75040 73.21178 94.15465 
CYP2S1 10.73499 27.94128 36.65159 34.57576 
NAV2 8.65916 17.41411 28.42555 17.50219 
HLA-DRA 51.12465 67.39359 87.83586 332.68451 
ZNF366 0.71171 0.88546 3.65602 4.85775 
CYP27B1 8.48124 13.28195 57.58230 68.93720 
ROBO1 0.23724 1.96770 2.92482 0.85725 
MT1E 11.56532 31.58152 28.33415 66.29402 
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TVP23A 0.05931 0.09838 0.82260 2.85750 
FBP1 16.25076 47.02793 11.42506 118.22909 
GFPT2 1.66066 3.64024 11.33366 10.28700 
ENTHD1 0.41517 1.67254 1.37101 2.42888 
CPED1 1.12688 8.26432 3.29042 4.07194 
HLA-DRB1 40.80483 51.06171 56.11989 254.38900 
ENO2 15.24250 82.64323 69.55576 44.43414 
ENTPD1 0.23724 0.59031 2.10221 2.14313 
MT1X 16.72523 36.00884 33.90958 96.51208 
ALOX15B 1.71997 11.70779 14.16707 6.71513 
RTN1 8.65916 24.20266 23.58132 54.93545 
EHF 0.88964 4.52570 7.76904 7.64381 
ITIH1 4.80406 11.31425 18.55430 16.28775 
TCF4 4.15165 10.23202 9.87125 12.07294 
PTGIR 49.34537 82.84000 115.07320 96.29777 
KCNE5 0.77102 2.85316 3.29042 6.07219 
MT1M 5.15991 9.14979 11.97346 40.36220 
CCL22 2.84685 7.77240 3.74742 15.07332 
HLA-DRB5 9.37088 11.51102 13.07027 69.00864 
EBI3 4.74475 54.40679 68.64176 34.71863 
FPR2 15.77628 77.62560 35.18918 52.14939 
HLA-DOA 0.35586 0.29515 1.37101 4.07194 
GCKR 1.60135 4.42732 12.70467 5.71500 
SPN 25.02854 54.89872 21.11351 73.08058 
HIST1H1C 6.70196 20.66081 20.10810 25.93182 
TNFRSF6B 1.83859 15.83995 14.44128 8.28675 
MT1F 15.59836 29.61382 40.94741 92.51158 
MOB3B 33.15392 81.06907 52.73807 75.00939 
CTSH 238.95733 1212.19909 613.93700 791.67056 
VEGFA 43.65167 104.97658 109.31497 58.65020 
ACE 1.06757 2.85316 3.29042 8.00100 
HSD11B1 0.59309 1.47577 1.09681 7.42950 
LAIR1 36.53455 78.51107 123.48204 159.44854 
RYR1 1.12688 2.26285 6.03243 4.50056 
PLXDC2 27.81608 46.14247 50.81866 79.22421 
CORO1A 29.59536 50.86494 108.03536 99.22671 
CCL24 121.16898 110.09259 138.74592 925.04440 
HAS1 2.13514 5.90309 2.55921 9.42975 
TSPAN33 23.54581 103.59919 108.30956 91.94008 
MEP1A 0.77102 3.34508 3.74742 1.71450 
ITGB2 350.22165 831.44992 683.40136 1174.00414 
CD1B 0.59309 1.08223 1.00541 2.92894 
PARP15 1.83859 4.82086 10.69386 2.42888 
SLC1A2 1.95721 3.04993 10.69386 8.35819 
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ADAMTS14 58.65694 112.25705 127.59507 151.66185 
FLT3 0.23724 0.49192 0.73120 1.14300 
PPBP 11.03154 9.14979 34.09238 54.43539 
CLIC2 6.34610 15.05287 11.97346 11.93007 
PECAM1 6.58334 9.05140 26.50614 26.50332 
CD207 0.11862 0.59031 0.27420 0.64294 
CLEC6A 0.17793 1.08223 2.01081 5.35781 
RARRES1 0.00000 0.00000 1.00541 1.00013 
TIAM1 30.60362 43.97800 37.38279 56.22133 
CLEC10A 0.05931 1.57416 5.57543 7.42950 
A2M 3.32132 21.74304 4.11302 37.50470 
TMEM173 8.06607 13.57710 27.87715 20.50257 
FPR1 5.87162 82.54484 33.08697 38.36195 
CYGB 0.11862 0.98385 0.63980 0.92869 
ITGA4 2.55030 7.57563 6.12383 7.14375 
CCR6 0.11862 0.78708 0.63980 0.57150 
ADCY6 0.35586 1.37739 1.55381 1.78594 
PTPRF 0.59309 1.27900 7.86044 3.71475 
GSN 139.02109 159.08822 114.52480 478.84567 
ZNF395 13.64115 48.01178 33.36117 19.35957 
ACTG1 319.55872 462.70370 391.19404 931.68809 
STEAP3 22.12238 49.09401 84.63684 70.58027 
TIFAB 0.29655 1.08223 4.66142 3.71475 
FAM124A 8.36262 19.67696 18.91990 16.28775 
LMO2 6.99850 22.43173 15.90368 21.85988 
NDRG2 1.48273 0.88546 1.64521 15.00188 
TNFAIP8L2 13.10736 26.07197 35.00638 35.36157 
CP 0.00000 0.68869 0.54840 0.42863 
HNMT 19.80932 56.86641 103.46534 77.58114 
UGCG 43.94822 76.24822 79.60982 78.36696 
TREM2 0.05931 0.00000 0.54840 3.64331 
INSM1 0.05931 0.29515 1.09681 0.64294 
C1orf54 1.71997 1.27900 2.37641 8.64394 
FABP5 4.50751 4.23055 6.76364 18.00225 
TNFSF13 3.02478 31.08960 17.00049 11.50144 
KCP 2.66892 9.83848 2.37641 5.07206 
ALDH2 1.95721 6.69017 16.17788 20.57400 
SPRED1 54.20874 59.52280 65.80834 93.72602 
MROH7 0.29655 1.47577 0.54840 0.42863 
PPP1R14C 0.35586 1.47577 0.45700 1.00013 
RAB3D 14.29355 23.02204 42.40982 35.29013 
PLEKHG1 0.17793 0.00000 0.63980 1.78594 
ZG16B 0.17793 0.68869 1.00541 0.57150 
FGL2 2.13514 1.08223 6.30663 10.71563 
57 
 
LY86 1.54204 4.62409 2.01081 5.42925 
C1QA 0.05931 0.59031 0.18280 0.78581 
BCL7A 1.36411 3.24670 6.21523 2.64319 
FADS2 12.39565 14.16741 19.65110 20.64544 
SIGLEC7 8.42193 62.57273 47.34545 28.43213 
CD4 2.60961 3.73862 17.64029 16.78782 
LDHA 138.07214 477.06788 382.14539 240.38724 
GCAT 0.41517 0.68869 0.63980 2.57175 
CD1D 0.23724 1.86931 2.28501 1.00013 
FAM20C 63.46099 107.33781 75.86240 158.66272 
LYZ 515.81332 1178.05956 2289.12493 3523.22687 
LXN 1.18619 3.24670 6.76364 9.28688 
CECR6 6.16817 19.38181 15.53808 18.14513 
NCEH1 35.22975 39.05876 56.02849 58.07870 
H2AFY2 0.29655 0.29515 1.82801 3.00038 
DLL4 0.05931 0.39354 0.73120 1.35731 
CD36 6.16817 10.23202 23.30712 31.78969 
PROCR 16.07283 31.67990 25.40933 37.07607 
PSD3 8.06607 18.10280 11.15086 9.21544 
MMP9 3682.22032 9469.33995 3620.92128 9371.88778 
LGALS1 133.80187 262.49064 250.52871 301.10913 
SMTNL2 0.00000 0.09838 1.00541 0.50006 
OTUD7B 4.27027 4.91924 6.85504 9.57263 
ACTB 1142.83166 1631.02317 2022.32694 3454.93261 
CD209 18.38590 38.46846 27.87715 44.00551 
HSPB1 13.40391 24.89135 17.09189 39.57638 
ARHGDIB 166.89648 223.43187 215.33952 527.70893 
FSCN1 9.72673 16.92219 17.00049 24.64594 
SYT1 0.11862 0.68869 0.00000 0.64294 
IGFBP7 2.60961 3.73862 6.30663 6.28650 
C6orf223 1.77928 2.36124 4.20442 4.71488 
CTSB 2730.54267 4791.53639 4164.66271 5224.72564 
RAMP1 0.41517 0.88546 0.18280 4.00050 
FRMD4A 2.55030 1.86931 6.48943 8.78681 
ADGRE3 18.62313 111.96190 81.25502 32.93270 
ITIH3 0.77102 0.49192 2.01081 3.00038 
ASGR2 0.00000 1.08223 0.63980 0.35719 
ZCWPW2 0.35586 0.29515 0.73120 1.07156 
PROS1 0.88964 1.47577 3.29042 3.07181 
CLDN23 12.81082 16.23349 10.05405 39.07632 
LMNB1 5.27853 8.46109 13.43587 14.85900 
TPI1 182.13898 361.07221 283.06728 342.32858 
HVCN1 6.82057 8.75625 10.60246 27.57488 
CD300LF 15.89490 16.52865 33.08697 58.29301 
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RCAN 19.57208 27.15420 30.61916 31.14676 
WNT5A 40.27104 99.07349 85.00244 42.07670 
SCD5 0.17793 0.19677 0.63980 1.07156 
CLEC4G 0.17793 0.49192 0.73120 0.92869 
CACNA2D3 0.11862 3.14831 0.54840 0.85725 
EMILIN1 87.54058 98.18803 141.94494 193.38136 
DTNA 3.02478 3.83701 3.83882 7.85813 
IL4I1 84.27857 184.37311 144.77835 180.66548 
SLA 7.05781 11.11748 87.83586 85.08208 
AUTS2 0.23724 0.49192 0.73120 0.92869 
CCND3 55.75078 80.18361 186.18277 208.24036 
SLAMF1 20.75827 141.37895 111.14298 47.64882 
NLRC5 18.56382 32.56537 50.63586 30.50382 
ACOT11 2.96547 5.11601 1.91941 7.78669 
PTPRO 3.49925 1.37739 11.05946 18.00225 
TTYH2 1.24550 4.82086 8.86585 5.71500 
STAT4 6.99850 12.49487 9.04865 9.78694 
TNNT1 0.47447 0.49192 0.63980 3.42900 
LDHB 2.60961 5.80470 7.22064 10.07269 
IDO1 149.28161 134.29525 319.71887 335.18483 
FAM200B 10.37913 19.18504 22.21032 23.07432 
TAX1BP3 40.09311 52.53748 60.87272 103.79871 
CERS6 35.76353 46.43762 46.70564 65.79395 
FCGRT 80.95725 181.02803 216.61913 290.67925 
TRAF5 1.54204 1.27900 2.92482 6.28650 
IVD 3.73649 5.31278 5.48403 10.64419 
COLEC12 0.77102 0.19677 0.82260 7.35806 
LGALS2 3.02478 1.47577 0.09140 30.64669 
DNAJC5B 4.27027 5.80470 10.23685 8.78681 
SPARC 1.71997 5.11601 8.04324 7.57238 
ZC4H2 0.23724 0.59031 1.37101 1.00013 
VSIG4 0.59309 0.78708 1.18821 2.71463 
AIF1 16.42869 19.38181 54.93169 67.22270 
RPGRIP1 0.00000 0.00000 2.01081 0.78581 
BUB1 0.11862 0.59031 0.54840 0.50006 
MT1G 38.37314 26.36713 29.88796 116.94321 
CLU 0.71171 1.96770 1.64521 4.42913 
LINC01420 8.54054 10.52717 8.68305 21.50269 
JAML 1.95721 1.08223 11.24226 37.07607 
PKIB 0.77102 0.49192 0.27420 4.92919 
PTRF 0.29655 1.18062 0.45700 0.92869 
MT-ND6 31.37464 41.22323 87.01325 34.00426 
FAT2 0.05931 0.68869 0.73120 0.00000 
CRIP1 1.60135 1.57416 3.38182 5.35781 
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GLRX 93.53083 135.47587 226.85598 258.10375 
TBX3 0.94895 0.29515 0.45700 6.92944 
AP2S1 39.26278 56.37449 69.00736 79.58139 
HLA-DQA2 0.94895 12.88841 0.91400 8.35819 
FZD3 0.41517 1.08223 1.46241 1.21444 
AK8 5.04129 5.80470 3.56462 11.35857 
TBC1D4 2.01652 1.57416 4.38722 7.64381 
GUCY1B3 0.29655 0.59031 0.82260 1.00013 
C16orf45 0.17793 0.29515 1.27961 1.85738 
ABCG1 2.31306 4.62409 5.30123 6.78656 
GP1BA 0.29655 1.96770 0.45700 0.57150 
BICC1 0.17793 0.78708 1.27961 0.35719 
FAIM 4.80406 5.80470 9.14005 7.50094 
CYFIP2 2.60961 6.78855 7.67764 8.35819 
PROB1 0.53378 1.08223 1.64521 1.71450 
IGFLR1 42.93996 45.65055 65.07714 117.87190 
FBXO6 9.31157 18.20119 16.63489 17.35932 
SLCO2B1 2.60961 2.06608 12.24766 33.86138 
RFTN1 93.17497 176.89587 238.73804 177.45079 
C10orf10 0.05931 0.00000 0.82260 0.57150 
SLAMF9 2.01652 0.78708 2.28501 6.92944 
S100A9 515.75401 824.56298 1736.51765 2072.54523 
CHI3L2 3.49925 4.42732 10.78526 13.21594 
SPATS2 2.90616 4.62409 8.86585 8.71538 
ALDOC 3.49925 15.54480 9.04865 9.35831 
UCP2 78.88142 91.69463 221.64616 273.60569 
DENND3 46.32059 138.62418 87.47026 64.65095 
PLEKHG2 34.99251 100.45088 118.54642 66.15114 
GPI 49.70123 81.26584 59.77591 69.29439 
PSRC1 0.11862 0.29515 0.63980 0.64294 
PLCL1 1.71997 1.96770 6.85504 6.42938 
SPECC1 3.79580 4.32893 6.58083 10.14413 
DBNDD2 11.56532 14.16741 24.67813 27.86063 
PLXNC1 52.25153 140.49349 155.83781 139.66034 
P4HA1 53.20048 132.62271 100.44912 80.15289 
LAP3 29.71398 39.35392 37.93120 48.72039 
IL21R 0.17793 0.29515 1.82801 2.28600 
NDP 2.84685 1.27900 8.50024 9.07256 
FZD2 0.11862 0.78708 3.10762 1.50019 
CARD9 4.80406 4.42732 9.68845 19.35957 
ATF7IP2 1.95721 5.80470 5.39263 4.50056 
METTL1 4.74475 4.42732 7.86044 13.14450 
LRP5 2.78754 8.46109 7.03784 5.14350 
ANXA6 12.03980 14.26580 37.29139 42.50532 
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MT2A 126.38820 273.80489 139.93413 453.62823 
CPM 34.99251 101.33634 50.08746 64.36520 
C3orf14 1.66066 6.98532 3.65602 3.14325 
DOCK1 12.39565 14.36418 29.52235 22.35994 
VASH1 9.43018 26.76066 58.49630 52.36370 
PLBD1 15.00526 12.59325 17.91449 51.64932 
KCTD12 76.09388 92.67848 145.69236 199.95361 
ZHX3 1.06757 3.34508 2.74201 2.21456 
TRPM4 4.56682 8.16594 17.09189 7.14375 
H1F0 143.05413 148.95458 245.68448 398.69278 
PLEKHO1 148.45128 200.01629 249.52330 316.96826 
FPR3 110.84915 58.34218 70.92677 406.69378 
ID3 0.65240 1.86931 7.40344 7.07231 
KIAA1211L 0.41517 0.88546 0.91400 0.71438 
SAMHD1 101.12242 75.06760 155.38081 261.17556 
SPINT2 15.71697 34.82822 38.02260 40.50507 
VMO1 1.18619 2.85316 6.76364 4.28625 
FAM101B 11.15016 42.69900 33.17837 19.57388 
CIITA 16.48800 15.83995 55.48009 74.43789 
TMEM176A 42.22825 31.77829 57.49090 111.65684 
MRC2 2.72823 7.47724 1.37101 6.07219 
ZNF680 0.29655 1.57416 1.27961 1.64306 
TNFRSF4 5.57508 15.24964 9.32285 9.71550 
ZFP36L1 144.35893 265.93411 181.70415 220.74193 
PRR11 0.29655 0.49192 3.01622 1.85738 
C2orf74 3.38063 2.75477 4.66142 8.00100 
NDN 0.17793 0.68869 0.00000 0.85725 
CENPE 0.65240 1.18062 3.74742 2.50031 
MCM6 6.28679 6.69017 6.48943 14.21607 
VGLL4 6.28679 29.12190 25.77493 12.14438 
IL16 40.62690 114.12636 76.50220 58.50733 
TPCN1 13.81908 27.05582 39.85061 33.43276 
GSPT2 2.13514 4.03378 2.46781 3.92906 
RGS14 7.82883 11.60941 16.63489 20.71688 
CXCR5 2.13514 9.93686 0.45700 3.71475 
CKB 10.31983 8.55948 14.98968 17.50219 
NR1H3 4.92268 2.26285 6.03243 18.64519 
SLC44A2 7.23574 15.83995 27.42014 14.07319 
GIPC3 0.35586 0.19677 0.63980 1.57163 
HAPLN3 0.23724 1.47577 0.73120 0.78581 
SMYD3 0.29655 0.68869 1.37101 0.71438 
THBS2 1.00826 1.67254 7.86044 2.21456 
MMP2 2.01652 2.45962 1.18821 5.57213 
STMN1 0.65240 1.77093 1.09681 2.57175 
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YPEL4 5.39715 5.80470 3.01622 16.50207 
CAMK1 13.52253 11.51102 9.59705 34.00426 
CATIP-AS1 1.00826 1.37739 2.10221 3.42900 
RNASE6 8.77778 9.05140 5.11843 19.00238 
DDX11 2.55030 13.28195 8.04324 4.71488 
LOXL2 1.42342 2.45962 3.93022 5.57213 
SLC16A10 5.75301 46.92955 38.47960 25.43176 
METTL21B 6.52403 7.28047 13.89287 19.50244 
ZNF469 3.14339 9.24817 10.69386 6.14363 
ST6GAL1 5.27853 8.36271 6.21523 9.92981 
VAMP8 17.31833 15.54480 38.84520 54.14964 
KCNE3 29.41743 30.20413 38.38820 63.65083 
ARL3 8.95571 11.21587 17.36609 21.35982 
DRAM2 36.17870 31.38475 61.42112 71.86614 
SLC11A1 682.11671 871.68930 946.81754 1209.50859 
CREBL2 53.73426 89.62855 134.45010 113.94284 
 
 
Supplementary Tables I and II. List of the top 500 genes that are differentially expressed in 
TSLPR+ and TSLPR- mono. Individual gene information are shown for each pair of TSLPR+ and 
TSLPR- mono. Table I, upregulated gene transcripts in TSLPR- vs TSLPR+ mono. Table II, 
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